EP1957480A1 - Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung - Google Patents
Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendungInfo
- Publication number
- EP1957480A1 EP1957480A1 EP06819882A EP06819882A EP1957480A1 EP 1957480 A1 EP1957480 A1 EP 1957480A1 EP 06819882 A EP06819882 A EP 06819882A EP 06819882 A EP06819882 A EP 06819882A EP 1957480 A1 EP1957480 A1 EP 1957480A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- general formula
- methoxy
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 94
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 51
- 238000011321 prophylaxis Methods 0.000 claims abstract description 40
- 201000010099 disease Diseases 0.000 claims abstract description 38
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims abstract description 22
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003726 vasopressin Drugs 0.000 claims abstract description 18
- 108010004977 Vasopressins Proteins 0.000 claims abstract description 17
- 102000002852 Vasopressins Human genes 0.000 claims abstract description 17
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 231
- -1 hydroxy, methoxy, ethoxy, propoxy, methyl Chemical group 0.000 claims description 131
- 239000000460 chlorine Substances 0.000 claims description 51
- 229910052801 chlorine Inorganic materials 0.000 claims description 46
- 229910052731 fluorine Inorganic materials 0.000 claims description 44
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 43
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 43
- 239000011737 fluorine Substances 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 229940002612 prodrug Drugs 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 230000035882 stress Effects 0.000 claims description 21
- 208000019901 Anxiety disease Diseases 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 208000028017 Psychotic disease Diseases 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 16
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 206010047163 Vasospasm Diseases 0.000 claims description 10
- 206010047700 Vomiting Diseases 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 208000019116 sleep disease Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000014311 Cushing syndrome Diseases 0.000 claims description 7
- 208000020401 Depressive disease Diseases 0.000 claims description 7
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 229930192474 thiophene Chemical group 0.000 claims description 6
- 206010002388 Angina unstable Diseases 0.000 claims description 5
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 5
- 208000008967 Enuresis Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000019025 Hypokalemia Diseases 0.000 claims description 5
- 206010021036 Hyponatraemia Diseases 0.000 claims description 5
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 claims description 5
- 206010021639 Incontinence Diseases 0.000 claims description 5
- 206010022714 Intestinal ulcer Diseases 0.000 claims description 5
- 206010028851 Necrosis Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 208000007814 Unstable Angina Diseases 0.000 claims description 5
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 201000010064 diabetes insipidus Diseases 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 5
- 201000008284 inappropriate ADH syndrome Diseases 0.000 claims description 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 201000003152 motion sickness Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000017074 necrotic cell death Effects 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 210000005227 renal system Anatomy 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 206010060800 Hot flush Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 4
- 238000007887 coronary angioplasty Methods 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000005346 nocturnal enuresis Diseases 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 230000001331 thermoregulatory effect Effects 0.000 claims description 4
- 230000001457 vasomotor Effects 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000024896 potassium deficiency disease Diseases 0.000 claims description 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical group C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical group C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 150000003536 tetrazoles Chemical group 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical group C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 150000003852 triazoles Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000027939 micturition Effects 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 139
- 150000003254 radicals Chemical class 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000011534 incubation Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 229960001723 oxytocin Drugs 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
- 101800000989 Oxytocin Proteins 0.000 description 11
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 11
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 11
- 150000001299 aldehydes Chemical class 0.000 description 11
- 239000000470 constituent Substances 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 10
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 10
- WOQVIOVWMBBGFI-XJDOXCRVSA-N 1-(4-methoxyphenyl)sulfonyl-3-[(2S)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3H-indol-2-one Chemical compound COc1ccc(cc1)S(=O)(=O)N1C(=O)C(N2CCC[C@H]2c2ncco2)c2ccccc12 WOQVIOVWMBBGFI-XJDOXCRVSA-N 0.000 description 9
- SGZFJWQQBHYNNF-UHFFFAOYSA-N 3-hydroxyindolin-2-one Chemical compound C1=CC=C2C(O)C(=O)NC2=C1 SGZFJWQQBHYNNF-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 150000001242 acetic acid derivatives Chemical class 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 239000008194 pharmaceutical composition Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 241000894007 species Species 0.000 description 5
- HBORMJBGPGQHSF-UHFFFAOYSA-N 1-(benzenesulfonyl)-3h-indol-2-one Chemical class O=C1CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 HBORMJBGPGQHSF-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000003939 benzylamines Chemical class 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 4
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- RPWXYSWZGLZUQA-LURJTMIESA-N 2-[(2s)-pyrrolidin-2-yl]-1,3-oxazole Chemical compound C1CCN[C@@H]1C1=NC=CO1 RPWXYSWZGLZUQA-LURJTMIESA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 102100028139 Oxytocin receptor Human genes 0.000 description 3
- 108090000876 Oxytocin receptors Proteins 0.000 description 3
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- FKMUTLRZQWAQME-UHFFFAOYSA-N [N].C1=CC=C2NC(=O)CC2=C1 Chemical compound [N].C1=CC=C2NC(=O)CC2=C1 FKMUTLRZQWAQME-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000005595 deprotonation Effects 0.000 description 3
- 238000010537 deprotonation reaction Methods 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical group C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000006103 sulfonylation Effects 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- CWJDVDQXFIORGV-BYPYZUCNSA-N (1s)-1-(1,3-oxazol-2-yl)ethanamine Chemical compound C[C@H](N)C1=NC=CO1 CWJDVDQXFIORGV-BYPYZUCNSA-N 0.000 description 2
- LWHHAVWYGIBIEU-LURJTMIESA-N (2s)-2-methylpyrrolidin-1-ium-2-carboxylate Chemical compound [O-]C(=O)[C@]1(C)CCC[NH2+]1 LWHHAVWYGIBIEU-LURJTMIESA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- KOURBIFKJIEMRK-UHFFFAOYSA-N 3-amino-1,3-dihydroindol-2-one Chemical class C1=CC=C2C(N)C(=O)NC2=C1 KOURBIFKJIEMRK-UHFFFAOYSA-N 0.000 description 2
- QMPNFQLVIGPNEI-UHFFFAOYSA-N 3-bromo-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1Br QMPNFQLVIGPNEI-UHFFFAOYSA-N 0.000 description 2
- 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 2
- XEJCDFZDXXUIAO-MWGAKABSSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O XEJCDFZDXXUIAO-MWGAKABSSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100513046 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) eth-1 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 238000007171 acid catalysis Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 150000001602 bicycloalkyls Chemical group 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 102000041441 vasopressin/oxytocin family Human genes 0.000 description 2
- 108091034376 vasopressin/oxytocin family Proteins 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- ZIWHMENIDGOELV-DMTCNVIQSA-N (2s,4r)-4-fluoropyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1C[C@@H](F)CN1 ZIWHMENIDGOELV-DMTCNVIQSA-N 0.000 description 1
- RRTVAMHPMSIVGB-RITPCOANSA-N (3r,5s)-5-(1,3-oxazol-2-yl)pyrrolidin-3-ol Chemical compound C1[C@@H](O)CN[C@@H]1C1=NC=CO1 RRTVAMHPMSIVGB-RITPCOANSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006060 1,1-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000006062 1,2-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006035 1,2-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006066 1,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ARTSAADOFVAXEG-KIYCQYGCSA-N 1-(3-bromo-4-methoxyphenyl)sulfonyl-5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(Br)C(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O ARTSAADOFVAXEG-KIYCQYGCSA-N 0.000 description 1
- UIWQGSOYOZPGKD-MWGAKABSSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCNCC3)=CC=2)OC)C1=O UIWQGSOYOZPGKD-MWGAKABSSA-N 0.000 description 1
- PKBLXLJTRBMGCF-LUWJBUJKSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound COC1=CC(CNCCC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(C#N)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O PKBLXLJTRBMGCF-LUWJBUJKSA-N 0.000 description 1
- NGKKEVFOFBXRFR-MWGAKABSSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCCC3)=CC=2)OC)C1=O NGKKEVFOFBXRFR-MWGAKABSSA-N 0.000 description 1
- IJXYEZQOSANHEV-LUWJBUJKSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-[(propan-2-ylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CNC(C)C)=CC=2)OC)C1=O IJXYEZQOSANHEV-LUWJBUJKSA-N 0.000 description 1
- HEHBWIGDHWMJGV-MWGAKABSSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O HEHBWIGDHWMJGV-MWGAKABSSA-N 0.000 description 1
- HLAPBZDAUUHFJS-URKOMERPSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCCC3)C=2)OC)C1=O HLAPBZDAUUHFJS-URKOMERPSA-N 0.000 description 1
- BHYLEYGWOFACPV-LUWJBUJKSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 BHYLEYGWOFACPV-LUWJBUJKSA-N 0.000 description 1
- PVSBWQAQMQONFK-MWGAKABSSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O PVSBWQAQMQONFK-MWGAKABSSA-N 0.000 description 1
- JYUJFWGRPFERJL-OEEKEXDXSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CC3)C(C)C)C=2)OC)C1=O JYUJFWGRPFERJL-OEEKEXDXSA-N 0.000 description 1
- GWPUYPDNQKHDSY-LUWJBUJKSA-N 1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(propan-2-ylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)C)C=2)OC)C1=O GWPUYPDNQKHDSY-LUWJBUJKSA-N 0.000 description 1
- YKBYJPGLXNQUDW-LUWJBUJKSA-N 1-(benzenesulfonyl)-5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC=CC=2)C(OC)=CC=C1CN1CCN(C)CC1 YKBYJPGLXNQUDW-LUWJBUJKSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- 125000006080 1-ethyl-1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006074 1-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006082 1-ethyl-2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006037 1-ethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006075 1-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006048 1-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006030 1-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006055 1-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WVDGSSCWFMSRHN-QMMMGPOBSA-N 1-o-tert-butyl 2-o-methyl (2s)-pyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C WVDGSSCWFMSRHN-QMMMGPOBSA-N 0.000 description 1
- ZROILLPDIUNLSE-UHFFFAOYSA-N 1-phenyl-1h-pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=CC=CC=C1 ZROILLPDIUNLSE-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006070 2,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
- FTYNTOQCCHAXGR-UHFFFAOYSA-N 2-(3-bromo-4-methoxyphenyl)-5,5-dimethyl-1,3-dioxane Chemical compound C1=C(Br)C(OC)=CC=C1C1OCC(C)(C)CO1 FTYNTOQCCHAXGR-UHFFFAOYSA-N 0.000 description 1
- AFRYFNQJSJPTOT-QMMMGPOBSA-N 2-[(2s)-2-methylpyrrolidin-2-yl]-1,3-oxazole Chemical compound N=1C=COC=1[C@]1(C)CCCN1 AFRYFNQJSJPTOT-QMMMGPOBSA-N 0.000 description 1
- HYSNXVPAKDTRDH-YFKPBYRVSA-N 2-[(2s)-pyrrolidin-2-yl]-1,3,4-oxadiazole Chemical compound C1CCN[C@@H]1C1=NN=CO1 HYSNXVPAKDTRDH-YFKPBYRVSA-N 0.000 description 1
- RWMPNQXGAMHCCO-RITPCOANSA-N 2-[(2s,4r)-4-fluoropyrrolidin-2-yl]-1,3-oxazole Chemical compound C1[C@@H](F)CN[C@@H]1C1=NC=CO1 RWMPNQXGAMHCCO-RITPCOANSA-N 0.000 description 1
- OQPDPWSFJRFWJW-RQJHMYQMSA-N 2-[(2s,4r)-4-methoxypyrrolidin-2-yl]-1,3-oxazole Chemical compound C1[C@@H](OC)CN[C@@H]1C1=NC=CO1 OQPDPWSFJRFWJW-RQJHMYQMSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- NESGFHKARGFUQK-UHFFFAOYSA-N 2-bromo-3-methoxypyridine-4-carbaldehyde Chemical compound COC1=C(Br)N=CC=C1C=O NESGFHKARGFUQK-UHFFFAOYSA-N 0.000 description 1
- RTWLIQFKXMWEJY-UHFFFAOYSA-N 2-bromopyridine-4-carbaldehyde Chemical compound BrC1=CC(C=O)=CC=N1 RTWLIQFKXMWEJY-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- VTEOIGRAYJMZAX-UEWDXFNNSA-N 3-[(2S)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1,3-dihydroindol-2-one Chemical compound O=C1Nc2ccccc2C1N1CCC[C@H]1c1ncco1 VTEOIGRAYJMZAX-UEWDXFNNSA-N 0.000 description 1
- ATFSESSLTKRXKN-YFKPBYRVSA-N 3-[(2s)-pyrrolidin-2-yl]-1,2,4-oxadiazole Chemical compound C1CCN[C@@H]1C1=NOC=N1 ATFSESSLTKRXKN-YFKPBYRVSA-N 0.000 description 1
- IXXNWQLONADGIA-HRNDKKHRSA-N 3-[(2s,4r)-4-fluoro-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](F)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O IXXNWQLONADGIA-HRNDKKHRSA-N 0.000 description 1
- PPCFZSBHWVWRFI-XFAIPLEMSA-N 3-[(2s,4r)-4-fluoro-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](F)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O PPCFZSBHWVWRFI-XFAIPLEMSA-N 0.000 description 1
- KMGRGXLHFUPVQL-DAIAQJPBSA-N 3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O KMGRGXLHFUPVQL-DAIAQJPBSA-N 0.000 description 1
- FPWGBVRZBRIXKM-PKBIYOIQSA-N 3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-2-oxoindole-5-carbonitrile Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 FPWGBVRZBRIXKM-PKBIYOIQSA-N 0.000 description 1
- APOAMYUCTNNHTM-HRNDKKHRSA-N 3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(C)CC3)=CC=2)OC)C1=O APOAMYUCTNNHTM-HRNDKKHRSA-N 0.000 description 1
- OCVAZVBLNVBIJD-OQTJJQELSA-N 3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 OCVAZVBLNVBIJD-OQTJJQELSA-N 0.000 description 1
- VNKBOGBMIAPNAP-DAIAQJPBSA-N 3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-5-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCOCC3)C=2)OC)C1=O VNKBOGBMIAPNAP-DAIAQJPBSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- SJLPLLRUURVHBF-MLAKCTNMSA-N 3-[2-methoxy-4-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound COC1=CC(CNC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(C#N)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O SJLPLLRUURVHBF-MLAKCTNMSA-N 0.000 description 1
- PVCFOOJHMQSVJT-MWGAKABSSA-N 3-[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCOCC3)=CC=2)OC)C1=O PVCFOOJHMQSVJT-MWGAKABSSA-N 0.000 description 1
- JPVAMAADZNVZFV-URKOMERPSA-N 3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(C)CC3)=CC=2)OC)C1=O JPVAMAADZNVZFV-URKOMERPSA-N 0.000 description 1
- YLKQDUUMAQPWQZ-MLAKCTNMSA-N 3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 YLKQDUUMAQPWQZ-MLAKCTNMSA-N 0.000 description 1
- PPPHKFMJJNLIPC-MWGAKABSSA-N 3-[2-methoxy-5-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCOCC3)C=2)OC)C1=O PPPHKFMJJNLIPC-MWGAKABSSA-N 0.000 description 1
- MLMAAMSOGSHRQM-KIYCQYGCSA-N 3-[2-methoxy-5-[(3-oxopiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CC(=O)NCC3)C=2)OC)C1=O MLMAAMSOGSHRQM-KIYCQYGCSA-N 0.000 description 1
- IBDQUVGBSHGHQD-AYZYUMGXSA-N 3-[2-methoxy-5-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CCC3)C=2)OC)C1=O IBDQUVGBSHGHQD-AYZYUMGXSA-N 0.000 description 1
- FPKZSMOKGAQPOI-URKOMERPSA-N 3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O FPKZSMOKGAQPOI-URKOMERPSA-N 0.000 description 1
- KXJKGNYUAGCODZ-MWGAKABSSA-N 3-[2-methoxy-5-[[2-methoxyethyl(methyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound COCCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 KXJKGNYUAGCODZ-MWGAKABSSA-N 0.000 description 1
- AZSJOGKDVXHBRG-MWGAKABSSA-N 3-[2-methoxy-5-[[methyl(propyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CCCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 AZSJOGKDVXHBRG-MWGAKABSSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- XRIZGKQEVXECLY-WXTKOERCSA-N 3-[4-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound COC1=CC(CNCC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(C#N)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O XRIZGKQEVXECLY-WXTKOERCSA-N 0.000 description 1
- ALKPLFUBQAUGII-AYZYUMGXSA-N 3-[4-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1CN(CC)CCN1CC1=CC=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)C(OC)=C1 ALKPLFUBQAUGII-AYZYUMGXSA-N 0.000 description 1
- ULALYGXBLPMWNL-XFAIPLEMSA-N 3-[4-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1CN(CC)CCN1CC1=CC=C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)C(OC)=C1 ULALYGXBLPMWNL-XFAIPLEMSA-N 0.000 description 1
- DWHSJRIOYUWKTC-WXTKOERCSA-N 3-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN(C)C)=CC=2)OC)C1=O DWHSJRIOYUWKTC-WXTKOERCSA-N 0.000 description 1
- RVLXPZLHWGZXOJ-CSNLXPDCSA-N 3-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC(CN(C)C)=CC=2)OC)C1=O RVLXPZLHWGZXOJ-CSNLXPDCSA-N 0.000 description 1
- CZIYKZWHUDJEPW-AYZYUMGXSA-N 3-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(CCO)CC3)=CC=2)OC)C1=O CZIYKZWHUDJEPW-AYZYUMGXSA-N 0.000 description 1
- BQDYCUXAPBRBBE-LUWJBUJKSA-N 3-[5-(azetidin-1-ylmethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCC3)C=2)OC)C1=O BQDYCUXAPBRBBE-LUWJBUJKSA-N 0.000 description 1
- GICKEACONHGOHO-YCIOTGQKSA-N 3-[5-(azetidin-1-ylmethyl)-2-methoxyphenyl]-5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCC3)C=2)OC)C1=O GICKEACONHGOHO-YCIOTGQKSA-N 0.000 description 1
- FNDSYRKSNWLBOB-WXTKOERCSA-N 3-[5-(azetidin-1-ylmethyl)-2-methoxyphenyl]-5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCC3)C=2)OC)C1=O FNDSYRKSNWLBOB-WXTKOERCSA-N 0.000 description 1
- OSYPDAKJPNTKTR-YCIOTGQKSA-N 3-[5-(azetidin-1-ylmethyl)-2-methoxyphenyl]-6-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCC3)C=2)OC)C1=O OSYPDAKJPNTKTR-YCIOTGQKSA-N 0.000 description 1
- LYYYILPPHXVHMF-MWGAKABSSA-N 3-[5-(diethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CCN(CC)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 LYYYILPPHXVHMF-MWGAKABSSA-N 0.000 description 1
- OMAJQXXQNQXFPG-WXTKOERCSA-N 3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 OMAJQXXQNQXFPG-WXTKOERCSA-N 0.000 description 1
- VVXNDDOVCGXYAW-CSNLXPDCSA-N 3-[5-(ethylaminomethyl)-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 VVXNDDOVCGXYAW-CSNLXPDCSA-N 0.000 description 1
- SNORCNUBQKEFMU-LMUZMDBKSA-N 3-[5-(hydroxymethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CO)C=2)OC)C1=O SNORCNUBQKEFMU-LMUZMDBKSA-N 0.000 description 1
- ICCGAKXSVQKSOU-AYZYUMGXSA-N 3-[5-[(4-acetylpiperazin-1-yl)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CC3)C(C)=O)C=2)OC)C1=O ICCGAKXSVQKSOU-AYZYUMGXSA-N 0.000 description 1
- HMWZWUHVNGRWAV-URKOMERPSA-N 3-[5-[(4-acetylpiperazin-1-yl)methyl]-2-methoxyphenyl]-5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CC3)C(C)=O)C=2)OC)C1=O HMWZWUHVNGRWAV-URKOMERPSA-N 0.000 description 1
- RGGLPMPQZHDUJJ-XFAIPLEMSA-N 3-[5-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1CN(CC)CCN1CC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 RGGLPMPQZHDUJJ-XFAIPLEMSA-N 0.000 description 1
- RLCSBQQQWBDWOB-URKOMERPSA-N 3-[5-[(4-hydroxypiperidin-1-yl)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCC(O)CC3)C=2)OC)C1=O RLCSBQQQWBDWOB-URKOMERPSA-N 0.000 description 1
- WTTUCFOBHGNPDT-WXTKOERCSA-N 3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O WTTUCFOBHGNPDT-WXTKOERCSA-N 0.000 description 1
- AYEFQLYFIQSMJA-CSNLXPDCSA-N 3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-fluoro-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](F)C2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O AYEFQLYFIQSMJA-CSNLXPDCSA-N 0.000 description 1
- UMMZSYSZCDTATM-CSNLXPDCSA-N 3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O UMMZSYSZCDTATM-CSNLXPDCSA-N 0.000 description 1
- UNLJSKYRJNXDHE-GZMKETDRSA-N 3-[5-[(tert-butylamino)methyl]-2-methoxyphenyl]-5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)(C)C)C=2)OC)C1=O UNLJSKYRJNXDHE-GZMKETDRSA-N 0.000 description 1
- NGYJQDOZBVIBQF-MIXNXMPVSA-N 3-[5-[(tert-butylamino)methyl]-2-methoxyphenyl]-5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)(C)C)C=2)OC)C1=O NGYJQDOZBVIBQF-MIXNXMPVSA-N 0.000 description 1
- KKQXFOZGQZWLLQ-AYZYUMGXSA-N 3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O KKQXFOZGQZWLLQ-AYZYUMGXSA-N 0.000 description 1
- HOGQOHUQDCMQFU-XFAIPLEMSA-N 3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-2-oxoindole-5-carbonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(C#N)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O HOGQOHUQDCMQFU-XFAIPLEMSA-N 0.000 description 1
- JBZFTDLHXAHMJG-LUWJBUJKSA-N 3-[5-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindole-5-carbonitrile Chemical compound CCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C#N)=C1 JBZFTDLHXAHMJG-LUWJBUJKSA-N 0.000 description 1
- BLVHMZIPQVMGCF-PKMDPOOCSA-N 3-[5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-3-yl]-4-methoxybenzaldehyde Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(C=O)C=2)OC)C1=O BLVHMZIPQVMGCF-PKMDPOOCSA-N 0.000 description 1
- TZUUPGZANQRCHD-UHFFFAOYSA-N 3-bromo-4-ethoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C=C1Br TZUUPGZANQRCHD-UHFFFAOYSA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- WTXXUAHMTVAQHW-UHFFFAOYSA-N 3-bromo-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1Br WTXXUAHMTVAQHW-UHFFFAOYSA-N 0.000 description 1
- BCZHCWCOQDRYGS-UHFFFAOYSA-N 3-bromothiophene-2-carbaldehyde Chemical compound BrC=1C=CSC=1C=O BCZHCWCOQDRYGS-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- IHLOHISMHMTTAA-UHFFFAOYSA-N 3-hydroxy-4-iodobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1I IHLOHISMHMTTAA-UHFFFAOYSA-N 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- RJAULZGZIUQMBV-RIXWGDDISA-N 4-[5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-4-(methylaminomethyl)phenyl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CNC)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O RJAULZGZIUQMBV-RIXWGDDISA-N 0.000 description 1
- VBXQJTUOJSFKDE-NBYSMXDESA-N 4-[5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C=1C=C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=1CN1CCCC1 VBXQJTUOJSFKDE-NBYSMXDESA-N 0.000 description 1
- FXBCPCDKEMVLGH-LUWJBUJKSA-N 4-[5-chloro-3-[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C=1C=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=1CN1CCNCC1 FXBCPCDKEMVLGH-LUWJBUJKSA-N 0.000 description 1
- TWIAVPFHLMETHH-WXTKOERCSA-N 4-[5-chloro-3-[2-methoxy-4-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CNCCC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O TWIAVPFHLMETHH-WXTKOERCSA-N 0.000 description 1
- QSIMSUBMLIFMGO-LUWJBUJKSA-N 4-[5-chloro-3-[2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C=1C=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=1CN1CCCC1 QSIMSUBMLIFMGO-LUWJBUJKSA-N 0.000 description 1
- XBEMUOLSLDCXPF-MWGAKABSSA-N 4-[5-chloro-3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C=1C=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=1CN1CCN(C)CC1 XBEMUOLSLDCXPF-MWGAKABSSA-N 0.000 description 1
- FMFQMVNMNPCRSF-MWGAKABSSA-N 4-[5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=C1CN1CCN(C)CC1 FMFQMVNMNPCRSF-MWGAKABSSA-N 0.000 description 1
- WEHRZOHDSSQWDW-NJCWMDGJSA-N 4-[5-chloro-3-[4-(ethylaminomethyl)-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CNCC)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O WEHRZOHDSSQWDW-NJCWMDGJSA-N 0.000 description 1
- MSKBRLFSOGJMRI-NJCWMDGJSA-N 4-[5-chloro-3-[4-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CNCCO)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O MSKBRLFSOGJMRI-NJCWMDGJSA-N 0.000 description 1
- YUHXSKDZXWKNTK-URKOMERPSA-N 4-[5-chloro-3-[4-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C1CN(CC)CCN1CC1=CC=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=C1 YUHXSKDZXWKNTK-URKOMERPSA-N 0.000 description 1
- HNYYGDGWMQMOAH-UDWLSXPGSA-N 4-[5-chloro-3-[4-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C1CN(CC)CCN1CC1=CC=C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=C1 HNYYGDGWMQMOAH-UDWLSXPGSA-N 0.000 description 1
- GFESUNAGAHVMIN-MLAKCTNMSA-N 4-[5-chloro-3-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CN(C)C)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O GFESUNAGAHVMIN-MLAKCTNMSA-N 0.000 description 1
- DPUXWVPFXCZPDC-NJCWMDGJSA-N 4-[5-chloro-3-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound COC1=CC(CN(C)C)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(=CC=2)C#N)C1=O DPUXWVPFXCZPDC-NJCWMDGJSA-N 0.000 description 1
- AUWLZQXCXLKWMJ-URKOMERPSA-N 4-[5-chloro-3-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-2-oxoindol-1-yl]sulfonylbenzonitrile Chemical compound C=1C=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(=CC=2)C#N)C(OC)=CC=1CN1CCN(CCO)CC1 AUWLZQXCXLKWMJ-URKOMERPSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- UYDZUCNMZXCLJI-UHFFFAOYSA-N 4-bromo-3-methoxyphenol Chemical compound COC1=CC(O)=CC=C1Br UYDZUCNMZXCLJI-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- ZDVHJQOCVBTMOF-UHFFFAOYSA-N 4-bromothiophene-3-carbaldehyde Chemical compound BrC1=CSC=C1C=O ZDVHJQOCVBTMOF-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- YLGYWVFYKSDNKL-ZETCQYMHSA-N 4-methyl-2-[(2s)-pyrrolidin-2-yl]-1,3-oxazole Chemical compound CC1=COC([C@H]2NCCC2)=N1 YLGYWVFYKSDNKL-ZETCQYMHSA-N 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006058 4-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- WUSXOEBIEDIKLY-MIXNXMPVSA-N 5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O WUSXOEBIEDIKLY-MIXNXMPVSA-N 0.000 description 1
- NTGPIJZKICXEOI-KIYCQYGCSA-N 5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCCC3)C=2)OC)C1=O NTGPIJZKICXEOI-KIYCQYGCSA-N 0.000 description 1
- YXOXEXRHKBNIIP-YCIOTGQKSA-N 5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 YXOXEXRHKBNIIP-YCIOTGQKSA-N 0.000 description 1
- BDUJTFZICANGOB-MIXNXMPVSA-N 5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O BDUJTFZICANGOB-MIXNXMPVSA-N 0.000 description 1
- FDOIWJJUNBPSJF-YCIOTGQKSA-N 5,6-dichloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(propan-2-ylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)C)C=2)OC)C1=O FDOIWJJUNBPSJF-YCIOTGQKSA-N 0.000 description 1
- HVRUICHLAQYRHK-MIXNXMPVSA-N 5,6-dichloro-3-(2-methoxy-3-methyl-5-morpholin-4-ylphenyl)-1-(4-methoxyphenyl)sulfonyl-3-[(2S)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound ClC=1C=C2C(C(N(C2=CC=1Cl)S(=O)(=O)C1=CC=C(C=C1)OC)=O)(N1[C@@H](CCC1)C=1OC=CN=1)C1=C(C(=CC(=C1)N1CCOCC1)C)OC HVRUICHLAQYRHK-MIXNXMPVSA-N 0.000 description 1
- AKEQDGAUGPQRLO-PAMMARIWSA-N 5,6-dichloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 AKEQDGAUGPQRLO-PAMMARIWSA-N 0.000 description 1
- GIRRZWCSLLDPPC-KIYCQYGCSA-N 5,6-dichloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O GIRRZWCSLLDPPC-KIYCQYGCSA-N 0.000 description 1
- FRQNEZUPMXEBDC-MIXNXMPVSA-N 5,6-dichloro-3-[2-methoxy-5-[[2-methoxyethyl(methyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COCCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 FRQNEZUPMXEBDC-MIXNXMPVSA-N 0.000 description 1
- GAVDAKSIZVHVAI-MIXNXMPVSA-N 5,6-dichloro-3-[2-methoxy-5-[[methyl(propan-2-yl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C(C)C)C=2)OC)C1=O GAVDAKSIZVHVAI-MIXNXMPVSA-N 0.000 description 1
- ZTJWCUARLQPELE-MIXNXMPVSA-N 5,6-dichloro-3-[2-methoxy-5-[[methyl(propyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 ZTJWCUARLQPELE-MIXNXMPVSA-N 0.000 description 1
- FOVQJDZWDLIHSF-MIXNXMPVSA-N 5,6-dichloro-3-[5-(diethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(CC)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 FOVQJDZWDLIHSF-MIXNXMPVSA-N 0.000 description 1
- KFOPFGLQRSKXTA-BSXJZHEVSA-N 5,6-dichloro-3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 KFOPFGLQRSKXTA-BSXJZHEVSA-N 0.000 description 1
- LSOWNIVWFRZJDV-SUHMBNCMSA-N 5,6-dichloro-3-[5-(hydroxymethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CO)C=2)OC)C1=O LSOWNIVWFRZJDV-SUHMBNCMSA-N 0.000 description 1
- NSUAMIDWMCVXDX-BSXJZHEVSA-N 5,6-dichloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O NSUAMIDWMCVXDX-BSXJZHEVSA-N 0.000 description 1
- KNJJQQJYBAHWLX-BRKUKBBPSA-N 5,6-dichloro-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O KNJJQQJYBAHWLX-BRKUKBBPSA-N 0.000 description 1
- WCKXJIOBGYQRIH-YCIOTGQKSA-N 5,6-dichloro-3-[5-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 WCKXJIOBGYQRIH-YCIOTGQKSA-N 0.000 description 1
- XHDJYQWGFIBCEP-UHFFFAOYSA-N 5-Chloro-1H-indole-2,3-dione Chemical compound ClC1=CC=C2NC(=O)C(=O)C2=C1 XHDJYQWGFIBCEP-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- VLMXWVKBXMBEQR-UHFFFAOYSA-N 5-bromo-6-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(C=O)C=C1Br VLMXWVKBXMBEQR-UHFFFAOYSA-N 0.000 description 1
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- XDSWDXPLLOJYIV-GYSVSWRBSA-N 5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O XDSWDXPLLOJYIV-GYSVSWRBSA-N 0.000 description 1
- IWLSKXOYZZYKNF-KIYCQYGCSA-N 5-chloro-1-(3-fluoro-4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(F)C(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O IWLSKXOYZZYKNF-KIYCQYGCSA-N 0.000 description 1
- SKESEGUKYPLIPU-LUWJBUJKSA-N 5-chloro-1-(4-chlorophenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(Cl)=CC=2)C(OC)=CC=C1CN1CCN(C)CC1 SKESEGUKYPLIPU-LUWJBUJKSA-N 0.000 description 1
- IXYVJKRVGZUUEZ-URKOMERPSA-N 5-chloro-1-(4-ethoxyphenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OCC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O IXYVJKRVGZUUEZ-URKOMERPSA-N 0.000 description 1
- GEXHKQCTBNGXTQ-URKOMERPSA-N 5-chloro-1-(4-ethylphenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O GEXHKQCTBNGXTQ-URKOMERPSA-N 0.000 description 1
- HRDMSOUOMVZVBY-LUWJBUJKSA-N 5-chloro-1-(4-fluorophenyl)sulfonyl-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(F)=CC=2)C(OC)=CC=C1CN1CCN(C)CC1 HRDMSOUOMVZVBY-LUWJBUJKSA-N 0.000 description 1
- PSFWHNGJIFPSKX-YCIOTGQKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[6-[(propan-2-ylamino)methyl]-1,3-benzodioxol-4-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C=3OCOC=3C=C(CNC(C)C)C=2)C1=O PSFWHNGJIFPSKX-YCIOTGQKSA-N 0.000 description 1
- UZZSPIKZKLMKMC-LUWJBUJKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-3-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=C(CN3CCCC3)C=CC=2)OC)C1=O UZZSPIKZKLMKMC-LUWJBUJKSA-N 0.000 description 1
- IBEWKNCMJHKXNI-LUWJBUJKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCNCC3)=CC=2)OC)C1=O IBEWKNCMJHKXNI-LUWJBUJKSA-N 0.000 description 1
- NCASXLLNWHLNQO-MWGAKABSSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(piperidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCCCC3)=CC=2)OC)C1=O NCASXLLNWHLNQO-MWGAKABSSA-N 0.000 description 1
- BGFKOKQXJHQFQY-WXTKOERCSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CNCCC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O BGFKOKQXJHQFQY-WXTKOERCSA-N 0.000 description 1
- RYUDYJOALUPOBZ-LUWJBUJKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCCC3)=CC=2)OC)C1=O RYUDYJOALUPOBZ-LUWJBUJKSA-N 0.000 description 1
- OQVDUZHSBYXILW-WXTKOERCSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-[(propan-2-ylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CNC(C)C)=CC=2)OC)C1=O OQVDUZHSBYXILW-WXTKOERCSA-N 0.000 description 1
- GAVRAOPEEHOZAA-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-(2-pyridin-2-ylpyrrolidin-1-yl)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2N=CC=CC=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O GAVRAOPEEHOZAA-UHFFFAOYSA-N 0.000 description 1
- JGLZOAYKBHSSOO-LUWJBUJKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O JGLZOAYKBHSSOO-LUWJBUJKSA-N 0.000 description 1
- LKFKCWPQYIIRPI-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2SC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O LKFKCWPQYIIRPI-UHFFFAOYSA-N 0.000 description 1
- GLDXBLZRIJYXOW-GIFGLUKTSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[[(1s)-1-(1,3-oxazol-2-yl)ethyl]amino]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N[C@@H](C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O GLDXBLZRIJYXOW-GIFGLUKTSA-N 0.000 description 1
- BFIFAHZAFOGEDK-MWGAKABSSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCCC3)C=2)OC)C1=O BFIFAHZAFOGEDK-MWGAKABSSA-N 0.000 description 1
- RVBZYOBWNYZNAB-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-(2-pyridin-2-ylpyrrolidin-1-yl)indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3C(CCC3)C=3N=CC=CC=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 RVBZYOBWNYZNAB-UHFFFAOYSA-N 0.000 description 1
- YMFFMHUOJQVCBO-WXTKOERCSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 YMFFMHUOJQVCBO-WXTKOERCSA-N 0.000 description 1
- ZNJFMJZOUOEWKK-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3C(CCC3)C=3SC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 ZNJFMJZOUOEWKK-UHFFFAOYSA-N 0.000 description 1
- UVRBDKHGGIPLKI-MFYZJFEASA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[[(1s)-1-(1,3-oxazol-2-yl)ethyl]amino]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N[C@@H](C)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 UVRBDKHGGIPLKI-MFYZJFEASA-N 0.000 description 1
- KDCQJSLKXZKPAJ-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-(1,3-oxazol-2-ylmethylamino)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(NCC=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O KDCQJSLKXZKPAJ-UHFFFAOYSA-N 0.000 description 1
- NUWNAUVHMPVPKS-LUWJBUJKSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O NUWNAUVHMPVPKS-LUWJBUJKSA-N 0.000 description 1
- AVYYCQYERAPODO-WKTASEEMSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s,4r)-4-[(2-methylpropan-2-yl)oxy]-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@H](C2)OC(C)(C)C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O AVYYCQYERAPODO-WKTASEEMSA-N 0.000 description 1
- FJTVWYZSYMFXLP-UHFFFAOYSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2SC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O FJTVWYZSYMFXLP-UHFFFAOYSA-N 0.000 description 1
- RHAMAHDONXLSOC-BSXJZHEVSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(2,2,2-trifluoroethylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNCC(F)(F)F)C=2)OC)C1=O RHAMAHDONXLSOC-BSXJZHEVSA-N 0.000 description 1
- XNVNYUHAORZILX-WXTKOERCSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-[(propan-2-ylamino)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)C)C=2)OC)C1=O XNVNYUHAORZILX-WXTKOERCSA-N 0.000 description 1
- CHPBCJRVFXSFBZ-KIYCQYGCSA-N 5-chloro-1-(4-methoxyphenyl)sulfonyl-3-[6-[(4-methylpiperazin-1-yl)methyl]-1,3-benzodioxol-4-yl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C=3OCOC=3C=C(CN3CCN(C)CC3)C=2)C1=O CHPBCJRVFXSFBZ-KIYCQYGCSA-N 0.000 description 1
- ITTUKBOASHIDDT-UHFFFAOYSA-N 5-chloro-1h-indole-2,3-dione;sodium Chemical compound [Na].ClC1=CC=C2NC(=O)C(=O)C2=C1 ITTUKBOASHIDDT-UHFFFAOYSA-N 0.000 description 1
- RYLDCRIZQTYEDM-DAIAQJPBSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(piperidin-1-ylmethyl)phenyl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC(CN3CCCCC3)=CC=2)OC)C1=O RYLDCRIZQTYEDM-DAIAQJPBSA-N 0.000 description 1
- SHFBHQOWTICQII-XFAIPLEMSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(CC3)C(C)C)=CC=2)OC)C1=O SHFBHQOWTICQII-XFAIPLEMSA-N 0.000 description 1
- XYRIAGRSXNUDFX-PKBIYOIQSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O XYRIAGRSXNUDFX-PKBIYOIQSA-N 0.000 description 1
- UMYILTGCLZFJRL-CSNLXPDCSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 UMYILTGCLZFJRL-CSNLXPDCSA-N 0.000 description 1
- QGFWURQFZPZGMY-PKBIYOIQSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O QGFWURQFZPZGMY-PKBIYOIQSA-N 0.000 description 1
- IZWIYAHUYLISMV-XRAWTGMFSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-4-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound COC1=CC(CNC)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O IZWIYAHUYLISMV-XRAWTGMFSA-N 0.000 description 1
- GEUSAZFUGOJRRR-DAIAQJPBSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(C)CC3)=CC=2)OC)C1=O GEUSAZFUGOJRRR-DAIAQJPBSA-N 0.000 description 1
- FFYUGCNGDYTFEZ-XRAWTGMFSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@@H](O)C3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 FFYUGCNGDYTFEZ-XRAWTGMFSA-N 0.000 description 1
- BXWUHGZQURGAOS-DAIAQJPBSA-N 5-chloro-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O BXWUHGZQURGAOS-DAIAQJPBSA-N 0.000 description 1
- TUZUZNLXRSNQOY-WXTKOERCSA-N 5-chloro-3-[2-ethoxy-5-(ethylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OCC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 TUZUZNLXRSNQOY-WXTKOERCSA-N 0.000 description 1
- CUMIGESXKVYBFA-MLAKCTNMSA-N 5-chloro-3-[2-ethoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCOC1=CC=C(CNC)C=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O CUMIGESXKVYBFA-MLAKCTNMSA-N 0.000 description 1
- ISBRSKWHLBCECD-URKOMERPSA-N 5-chloro-3-[2-ethoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C(OCC)=CC=C1CN1CCN(C)CC1 ISBRSKWHLBCECD-URKOMERPSA-N 0.000 description 1
- WJSXUDVVFDOKDD-LUWJBUJKSA-N 5-chloro-3-[2-ethoxy-5-[(propan-2-ylamino)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCOC1=CC=C(CNC(C)C)C=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O WJSXUDVVFDOKDD-LUWJBUJKSA-N 0.000 description 1
- BPWMVONAYYCIDN-PTYUOYDSSA-N 5-chloro-3-[2-fluoro-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)F)C1=O BPWMVONAYYCIDN-PTYUOYDSSA-N 0.000 description 1
- NHUASUIFLVGBOL-QGFKTNLFSA-N 5-chloro-3-[2-fluoro-5-[(propan-2-ylamino)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC(C)C)C=2)F)C1=O NHUASUIFLVGBOL-QGFKTNLFSA-N 0.000 description 1
- NHCOPEIRHVLUJZ-MWGAKABSSA-N 5-chloro-3-[2-methoxy-3-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=C(CN3CCN(C)CC3)C=CC=2)OC)C1=O NHCOPEIRHVLUJZ-MWGAKABSSA-N 0.000 description 1
- IVAQSIJCZMLQJV-LMUZMDBKSA-N 5-chloro-3-[2-methoxy-4-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CNC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O IVAQSIJCZMLQJV-LMUZMDBKSA-N 0.000 description 1
- NPCZLMSKWADBBT-LUWJBUJKSA-N 5-chloro-3-[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCOCC3)=CC=2)OC)C1=O NPCZLMSKWADBBT-LUWJBUJKSA-N 0.000 description 1
- KLBAHQKJUHKTHB-MIXNXMPVSA-N 5-chloro-3-[2-methoxy-4-[(3-oxopiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CC(=O)NCC3)=CC=2)OC)C1=O KLBAHQKJUHKTHB-MIXNXMPVSA-N 0.000 description 1
- NWSCZRLHNIDXBL-MWGAKABSSA-N 5-chloro-3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(C)CC3)=CC=2)OC)C1=O NWSCZRLHNIDXBL-MWGAKABSSA-N 0.000 description 1
- AVHBKONDUJCHCI-LUWJBUJKSA-N 5-chloro-3-[2-methoxy-4-[[2-methoxyethyl(methyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CN(C)CCOC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O AVHBKONDUJCHCI-LUWJBUJKSA-N 0.000 description 1
- VVVYLDUFPHFXRQ-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-(1,3-oxazol-2-ylmethylamino)indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(NCC=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 VVVYLDUFPHFXRQ-UHFFFAOYSA-N 0.000 description 1
- YOPZHFZLUKMZGW-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-(2-pyridin-2-ylpyrrolidin-1-yl)indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3C(CCC3)C=3N=CC=CC=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 YOPZHFZLUKMZGW-UHFFFAOYSA-N 0.000 description 1
- CCDGXHHJZYGCCT-LMUZMDBKSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 CCDGXHHJZYGCCT-LMUZMDBKSA-N 0.000 description 1
- LTAOVEKVTMZBFQ-CYZZXXEPSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-methyl-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3[C@](CCC3)(C)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 LTAOVEKVTMZBFQ-CYZZXXEPSA-N 0.000 description 1
- BYMIFLRZZZMXSM-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CNCC1=CC=C(OC)C(C2(N3C(CCC3)C=3SC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 BYMIFLRZZZMXSM-UHFFFAOYSA-N 0.000 description 1
- QSAWLFXMDLEOPD-PKMDPOOCSA-N 5-chloro-3-[2-methoxy-5-(methylaminomethyl)pyridin-3-yl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CNCC1=CN=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 QSAWLFXMDLEOPD-PKMDPOOCSA-N 0.000 description 1
- VUMJPTDBHZPNHD-LUWJBUJKSA-N 5-chloro-3-[2-methoxy-5-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCOCC3)C=2)OC)C1=O VUMJPTDBHZPNHD-LUWJBUJKSA-N 0.000 description 1
- PCHPBMYZBLYSGK-URKOMERPSA-N 5-chloro-3-[2-methoxy-5-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CCC3)C=2)OC)C1=O PCHPBMYZBLYSGK-URKOMERPSA-N 0.000 description 1
- CJQDGFBKCVGPNQ-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-(1,3-oxazol-2-ylmethylamino)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(NCC=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O CJQDGFBKCVGPNQ-UHFFFAOYSA-N 0.000 description 1
- GPCYJTBXAAWNRY-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-(2-pyridin-2-ylpyrrolidin-1-yl)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2N=CC=CC=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O GPCYJTBXAAWNRY-UHFFFAOYSA-N 0.000 description 1
- NLVWKQLSMMJKSE-URKOMERPSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(5-methyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC(C)=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O NLVWKQLSMMJKSE-URKOMERPSA-N 0.000 description 1
- VQAIXFISKNQQDP-TYIYNAFKSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-methyl-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@](CCC2)(C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O VQAIXFISKNQQDP-TYIYNAFKSA-N 0.000 description 1
- MVUDFDXLPFUMCD-WYJOJVMQSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s,4r)-4-[(2-methylpropan-2-yl)oxy]-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@H](C2)OC(C)(C)C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O MVUDFDXLPFUMCD-WYJOJVMQSA-N 0.000 description 1
- PVKXPVKKLWBMKA-UHFFFAOYSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2SC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O PVKXPVKKLWBMKA-UHFFFAOYSA-N 0.000 description 1
- AQYAQSWXSIEYMC-LJPZCQIFSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[[(1s)-1-(1,3-oxazol-2-yl)ethyl]amino]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N[C@@H](C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O AQYAQSWXSIEYMC-LJPZCQIFSA-N 0.000 description 1
- BFHIFYYSGIOVLZ-LUWJBUJKSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-[4-(trifluoromethoxy)phenyl]sulfonylindol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC(F)(F)F)=CC=2)C(OC)=CC=C1CN1CCN(C)CC1 BFHIFYYSGIOVLZ-LUWJBUJKSA-N 0.000 description 1
- YUHFQUPGLRSDDX-BSXJZHEVSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-thiophen-2-ylsulfonylindol-2-one Chemical compound C1=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2SC=CC=2)C(OC)=CC=C1CN1CCN(C)CC1 YUHFQUPGLRSDDX-BSXJZHEVSA-N 0.000 description 1
- KZOIBGSRTOKDRA-UDWLSXPGSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-3-[(2s,4r)-4-methoxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound N1([C@@H](C[C@H](C1)OC)C=1OC=CN=1)C(C1=CC(Cl)=CC=C11)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C(=O)N1S(=O)(=O)C1=CC=C(OC)C=C1 KZOIBGSRTOKDRA-UDWLSXPGSA-N 0.000 description 1
- HBEAWCGQFFEGRW-LUWJBUJKSA-N 5-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]pyridin-3-yl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=NC=C(CN3CCN(C)CC3)C=2)OC)C1=O HBEAWCGQFFEGRW-LUWJBUJKSA-N 0.000 description 1
- XPVPFRTYTHSJLS-MLAKCTNMSA-N 5-chloro-3-[3-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=C(CN(C)C)C=CC=2)OC)C1=O XPVPFRTYTHSJLS-MLAKCTNMSA-N 0.000 description 1
- PSSXMBMUUBWCPB-LUWJBUJKSA-N 5-chloro-3-[4-(diethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CN(CC)CC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O PSSXMBMUUBWCPB-LUWJBUJKSA-N 0.000 description 1
- VSKBUGCGGHQWBJ-MLAKCTNMSA-N 5-chloro-3-[4-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CNCC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O VSKBUGCGGHQWBJ-MLAKCTNMSA-N 0.000 description 1
- SAZMVVIGNRWEPD-PKMDPOOCSA-N 5-chloro-3-[4-(hydroxymethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CO)=CC=2)OC)C1=O SAZMVVIGNRWEPD-PKMDPOOCSA-N 0.000 description 1
- LJYJLQAFZVDSLF-MLAKCTNMSA-N 5-chloro-3-[4-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CNCCO)=CC=2)OC)C1=O LJYJLQAFZVDSLF-MLAKCTNMSA-N 0.000 description 1
- JMUPTVYRAAVDGS-BRKUKBBPSA-N 5-chloro-3-[4-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-6-fluoro-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1CN(CC)CCN1CC1=CC=C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=C(F)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)C(OC)=C1 JMUPTVYRAAVDGS-BRKUKBBPSA-N 0.000 description 1
- CHCBHOFMXSUUKS-MLAKCTNMSA-N 5-chloro-3-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN(C)C)=CC=2)OC)C1=O CHCBHOFMXSUUKS-MLAKCTNMSA-N 0.000 description 1
- HXBHODMOWKPVFV-URKOMERPSA-N 5-chloro-3-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(CCO)CC3)=CC=2)OC)C1=O HXBHODMOWKPVFV-URKOMERPSA-N 0.000 description 1
- BAVCSLNOYMKSLG-WXTKOERCSA-N 5-chloro-3-[4-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COC1=CC(CN(C)CC)=CC=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O BAVCSLNOYMKSLG-WXTKOERCSA-N 0.000 description 1
- RUIUZAQEMKZNEI-CSNLXPDCSA-N 5-chloro-3-[4-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound COC1=CC(CN(C)CC)=CC=C1C1(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O RUIUZAQEMKZNEI-CSNLXPDCSA-N 0.000 description 1
- PVCVMQVAKGVVTN-LUWJBUJKSA-N 5-chloro-3-[5-(diethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(CC)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 PVCVMQVAKGVVTN-LUWJBUJKSA-N 0.000 description 1
- YUNAQNDNTSOACI-NPHAVVRNSA-N 5-chloro-3-[5-(ethylaminomethyl)-2-fluorophenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(F)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 YUNAQNDNTSOACI-NPHAVVRNSA-N 0.000 description 1
- UDJXTXLWLSZHSV-MLAKCTNMSA-N 5-chloro-3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 UDJXTXLWLSZHSV-MLAKCTNMSA-N 0.000 description 1
- NGJIDAKBPYPEBI-JEFWXSHNSA-N 5-chloro-3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-methyl-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@](CCC3)(C)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 NGJIDAKBPYPEBI-JEFWXSHNSA-N 0.000 description 1
- HFQVGYLIKFDZGL-YTHVBODASA-N 5-chloro-3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s,4r)-4-[(2-methylpropan-2-yl)oxy]-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](C[C@H](C3)OC(C)(C)C)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 HFQVGYLIKFDZGL-YTHVBODASA-N 0.000 description 1
- LDZGDUFMUHYADL-PKMDPOOCSA-N 5-chloro-3-[5-(hydroxymethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CO)C=2)OC)C1=O LDZGDUFMUHYADL-PKMDPOOCSA-N 0.000 description 1
- RVZYCZYMVLKFDZ-UHFFFAOYSA-N 5-chloro-3-[5-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-(1,3-oxazol-2-ylmethylamino)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(NCC=2OC=CN=2)(C=2C(=CC=C(CNCCO)C=2)OC)C1=O RVZYCZYMVLKFDZ-UHFFFAOYSA-N 0.000 description 1
- ZGSNYDPWEGHJQI-MLAKCTNMSA-N 5-chloro-3-[5-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNCCO)C=2)OC)C1=O ZGSNYDPWEGHJQI-MLAKCTNMSA-N 0.000 description 1
- UZCRYHKHVQBKIK-QUZMYUOTSA-N 5-chloro-3-[5-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[[(1s)-1-(1,3-oxazol-2-yl)ethyl]amino]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N[C@@H](C)C=2OC=CN=2)(C=2C(=CC=C(CNCCO)C=2)OC)C1=O UZCRYHKHVQBKIK-QUZMYUOTSA-N 0.000 description 1
- BARCVEHICODYJH-URKOMERPSA-N 5-chloro-3-[5-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1CN(CC)CCN1CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 BARCVEHICODYJH-URKOMERPSA-N 0.000 description 1
- BLOCEDWGOSJEIW-NWDJCJOJSA-N 5-chloro-3-[5-[(4-ethylpiperazin-1-yl)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-methyl-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1CN(CC)CCN1CC1=CC=C(OC)C(C2(N3[C@](CCC3)(C)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 BLOCEDWGOSJEIW-NWDJCJOJSA-N 0.000 description 1
- AGYFYDFELHBHDN-WXTKOERCSA-N 5-chloro-3-[5-[(cyclopropylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNC3CC3)C=2)OC)C1=O AGYFYDFELHBHDN-WXTKOERCSA-N 0.000 description 1
- BABRISLOUNTQLP-WXTKOERCSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-ethoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCOC1=CC=C(CN(C)C)C=C1C1(N2[C@@H](CCC2)C=2OC=CN=2)C2=CC(Cl)=CC=C2N(S(=O)(=O)C=2C=CC(OC)=CC=2)C1=O BABRISLOUNTQLP-WXTKOERCSA-N 0.000 description 1
- DENNRPYHNWYHGS-NPHAVVRNSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-fluorophenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)F)C1=O DENNRPYHNWYHGS-NPHAVVRNSA-N 0.000 description 1
- KWYPOXDDWMKWGT-UHFFFAOYSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-(1,3-oxazol-2-ylmethylamino)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(NCC=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O KWYPOXDDWMKWGT-UHFFFAOYSA-N 0.000 description 1
- BOUJUCRUVVWJBI-UHFFFAOYSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-(2-pyridin-2-ylpyrrolidin-1-yl)indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2N=CC=CC=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O BOUJUCRUVVWJBI-UHFFFAOYSA-N 0.000 description 1
- OAIPTJXKMLWSCX-MLAKCTNMSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O OAIPTJXKMLWSCX-MLAKCTNMSA-N 0.000 description 1
- KQCDBNLKAMTAIB-WXTKOERCSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(5-methyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC(C)=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O KQCDBNLKAMTAIB-WXTKOERCSA-N 0.000 description 1
- QPFVVJUECPDKBE-YTHVBODASA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s,4r)-4-[(2-methylpropan-2-yl)oxy]-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@H](C2)OC(C)(C)C)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O QPFVVJUECPDKBE-YTHVBODASA-N 0.000 description 1
- VHPZLTVEWZHIID-UHFFFAOYSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2C(CCC2)C=2SC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O VHPZLTVEWZHIID-UHFFFAOYSA-N 0.000 description 1
- MVICXMOPAMHMMT-QUZMYUOTSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[[(1s)-1-(1,3-oxazol-2-yl)ethyl]amino]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N[C@@H](C)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O MVICXMOPAMHMMT-QUZMYUOTSA-N 0.000 description 1
- AAMSFJOMBKEPAR-OQTJJQELSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-hydroxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@@H](O)C2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O AAMSFJOMBKEPAR-OQTJJQELSA-N 0.000 description 1
- XANKVRAACZWBJA-IAOIWNPBSA-N 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-3-[(2s,4r)-4-methoxy-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]-1-(4-methoxyphenyl)sulfonylindol-2-one Chemical compound N1([C@@H](C[C@H](C1)OC)C=1OC=CN=1)C(C1=CC(Cl)=CC=C11)(C=2C(=CC=C(CN(C)C)C=2)OC)C(=O)N1S(=O)(=O)C1=CC=C(OC)C=C1 XANKVRAACZWBJA-IAOIWNPBSA-N 0.000 description 1
- BDZIXCGROPCZRH-URKOMERPSA-N 5-chloro-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O BDZIXCGROPCZRH-URKOMERPSA-N 0.000 description 1
- AQQVJZFKRYOCAV-AYZYUMGXSA-N 5-chloro-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(5-methyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC(C)=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O AQQVJZFKRYOCAV-AYZYUMGXSA-N 0.000 description 1
- ZVWIVWPGAMBHKY-NWDJCJOJSA-N 5-chloro-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-methyl-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@](CCC2)(C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O ZVWIVWPGAMBHKY-NWDJCJOJSA-N 0.000 description 1
- IWHNTAMYHPICQT-DOSHYGIUSA-N 5-chloro-3-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s,4r)-4-[(2-methylpropan-2-yl)oxy]-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC=C(Cl)C=C2C(N2[C@@H](C[C@H](C2)OC(C)(C)C)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(CCO)CC3)C=2)OC)C1=O IWHNTAMYHPICQT-DOSHYGIUSA-N 0.000 description 1
- CHBOKKWOTPZYJK-WXTKOERCSA-N 5-chloro-3-[5-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC(Cl)=CC=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 CHBOKKWOTPZYJK-WXTKOERCSA-N 0.000 description 1
- WWYDHOGWXMEIJL-MIXNXMPVSA-N 5-chloro-6-fluoro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-4-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(F)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCNCC3)=CC=2)OC)C1=O WWYDHOGWXMEIJL-MIXNXMPVSA-N 0.000 description 1
- OBJNZGHLKYJLOU-MIXNXMPVSA-N 5-chloro-6-fluoro-3-(2-methoxy-3-methyl-5-piperazin-1-ylphenyl)-1-(4-methoxyphenyl)sulfonyl-3-[(2S)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound ClC=1C=C2C(C(N(C2=CC=1F)S(=O)(=O)C1=CC=C(C=C1)OC)=O)(N1[C@@H](CCC1)C=1OC=CN=1)C1=C(C(=CC(=C1)N1CCNCC1)C)OC OBJNZGHLKYJLOU-MIXNXMPVSA-N 0.000 description 1
- GWORTHSAWLAGQR-KIYCQYGCSA-N 5-chloro-6-fluoro-3-[2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(F)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(C)CC3)=CC=2)OC)C1=O GWORTHSAWLAGQR-KIYCQYGCSA-N 0.000 description 1
- WAEOPHKLASNLQX-KIYCQYGCSA-N 5-chloro-6-fluoro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(F)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O WAEOPHKLASNLQX-KIYCQYGCSA-N 0.000 description 1
- VQTVOJJXLKXKKC-BRKUKBBPSA-N 5-chloro-6-fluoro-3-[4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(F)=C(Cl)C=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC(CN3CCN(CCO)CC3)=CC=2)OC)C1=O VQTVOJJXLKXKKC-BRKUKBBPSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- NISBCEKBWGTZJY-ZETCQYMHSA-N 5-methyl-2-[(2s)-pyrrolidin-2-yl]-1,3-oxazole Chemical compound O1C(C)=CN=C1[C@H]1NCCC1 NISBCEKBWGTZJY-ZETCQYMHSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 1
- VBIHPWZCNOEVDM-MIXNXMPVSA-N 6-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperazin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCNCC3)C=2)OC)C1=O VBIHPWZCNOEVDM-MIXNXMPVSA-N 0.000 description 1
- QLCDTWLRNJMYJY-KIYCQYGCSA-N 6-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(piperidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCCC3)C=2)OC)C1=O QLCDTWLRNJMYJY-KIYCQYGCSA-N 0.000 description 1
- KSEJOSCJBFCRMB-YCIOTGQKSA-N 6-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(propylaminomethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 KSEJOSCJBFCRMB-YCIOTGQKSA-N 0.000 description 1
- AGGGEXWEWNGRKT-MIXNXMPVSA-N 6-chloro-1-(4-methoxyphenyl)sulfonyl-3-[2-methoxy-5-(pyrrolidin-1-ylmethyl)phenyl]-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCCC3)C=2)OC)C1=O AGGGEXWEWNGRKT-MIXNXMPVSA-N 0.000 description 1
- DWJNTPSKJVTTKL-MIXNXMPVSA-N 6-chloro-3-[2-methoxy-5-(morpholin-4-ylmethyl)phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCOCC3)C=2)OC)C1=O DWJNTPSKJVTTKL-MIXNXMPVSA-N 0.000 description 1
- RPWPYHVKGLAFJT-KIYCQYGCSA-N 6-chloro-3-[2-methoxy-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN3CCN(C)CC3)C=2)OC)C1=O RPWPYHVKGLAFJT-KIYCQYGCSA-N 0.000 description 1
- NWINVODFERLAEB-MIXNXMPVSA-N 6-chloro-3-[2-methoxy-5-[[2-methoxyethyl(methyl)amino]methyl]phenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound COCCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 NWINVODFERLAEB-MIXNXMPVSA-N 0.000 description 1
- CNMWYMOTGTWGLJ-MIXNXMPVSA-N 6-chloro-3-[5-(diethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(CC)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 CNMWYMOTGTWGLJ-MIXNXMPVSA-N 0.000 description 1
- VFVYVEFBMSUGML-BSXJZHEVSA-N 6-chloro-3-[5-(ethylaminomethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCNCC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 VFVYVEFBMSUGML-BSXJZHEVSA-N 0.000 description 1
- MEZYHCGTPUFZAY-SUHMBNCMSA-N 6-chloro-3-[5-(hydroxymethyl)-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CO)C=2)OC)C1=O MEZYHCGTPUFZAY-SUHMBNCMSA-N 0.000 description 1
- WRFTUVSMPKCALL-BSXJZHEVSA-N 6-chloro-3-[5-[(2-hydroxyethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CNCCO)C=2)OC)C1=O WRFTUVSMPKCALL-BSXJZHEVSA-N 0.000 description 1
- BOHZCMRHAHHTKL-BSXJZHEVSA-N 6-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C2=CC(Cl)=CC=C2C(N2[C@@H](CCC2)C=2OC=CN=2)(C=2C(=CC=C(CN(C)C)C=2)OC)C1=O BOHZCMRHAHHTKL-BSXJZHEVSA-N 0.000 description 1
- MXXLIVHSRHNOHH-YCIOTGQKSA-N 6-chloro-3-[5-[[ethyl(methyl)amino]methyl]-2-methoxyphenyl]-1-(4-methoxyphenyl)sulfonyl-3-[(2s)-2-(1,3-oxazol-2-yl)pyrrolidin-1-yl]indol-2-one Chemical compound CCN(C)CC1=CC=C(OC)C(C2(N3[C@@H](CCC3)C=3OC=CN=3)C3=CC=C(Cl)C=C3N(C2=O)S(=O)(=O)C=2C=CC(OC)=CC=2)=C1 MXXLIVHSRHNOHH-YCIOTGQKSA-N 0.000 description 1
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 101000986765 Homo sapiens Oxytocin receptor Proteins 0.000 description 1
- 101000954157 Homo sapiens Vasopressin V1a receptor Proteins 0.000 description 1
- 101000954141 Homo sapiens Vasopressin V1b receptor Proteins 0.000 description 1
- 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000017937 Vasopressin/oxytocin receptor Human genes 0.000 description 1
- 108060003373 Vasopressin/oxytocin receptor Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- XSXCDEAQYCMWIS-SFYZADRCSA-N [(3r,5s)-5-(1,3-oxazol-2-yl)pyrrolidin-3-yl] acetate Chemical compound C1[C@@H](OC(=O)C)CN[C@@H]1C1=NC=CO1 XSXCDEAQYCMWIS-SFYZADRCSA-N 0.000 description 1
- SMCUOBSDAGTZFC-UHFFFAOYSA-M [Br-].C1=CC([Mg+])=CC=C1CN1CCCC1 Chemical compound [Br-].C1=CC([Mg+])=CC=C1CN1CCCC1 SMCUOBSDAGTZFC-UHFFFAOYSA-M 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000046595 human AVPR2 Human genes 0.000 description 1
- 102000052321 human OXTR Human genes 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- XFNBNGUTGPHKQN-UHFFFAOYSA-M magnesium;1-(phenylmethyl)pyrrolidine;bromide Chemical compound [Mg+2].[Br-].C=1C=C[C-]=CC=1CN1CCCC1 XFNBNGUTGPHKQN-UHFFFAOYSA-M 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004626 naphthothienyl group Chemical group C1(=CSC2=C1C1=CC=CC=C1C=C2)* 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000626 sulfinic acid group Chemical group 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- MDMSZBHMBCNYNO-QMMMGPOBSA-N tert-butyl (2s)-2-cyanopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C#N MDMSZBHMBCNYNO-QMMMGPOBSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- DSPOVSQQYMUIGB-UHFFFAOYSA-N trimethyl(triazol-2-yl)silane Chemical compound C[Si](C)(C)N1N=CC=N1 DSPOVSQQYMUIGB-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to novel substituted oxindole derivatives, medicaments containing them and their use for the treatment of diseases.
- Vasopressin is an endogenous hormone that exerts various effects on organs and tissues. Vasopressin is related to oxytocin (OT), so that both peptides to a vasopressin / oxytocin family summarizes. It is believed that the vasopressin / oxytocin system plays a role in various disease states.
- V1a, V1b and V3 and V2 receptors vasopressin receptors
- OT receptor oxytocin receptor
- Antagonists of these receptors in particular also antagonists which specifically bind only to one of the above receptors, represent new therapeutic approaches to the treatment of diseases (M. Thibonnier, Exp. Olpin Invest. Drugs 1998, 7 (5), 729-740 ). For example, it has been found that a selective antagonist of vasopressin V1 b receptor in
- V1b receptor antagonists are useful for the treatment of emotional disorders or diseases, e.g. Stress, anxiety and / or depression, of particular interest.
- novel substituted oxindoles which carry an arylsulfonyl group in the 1-position.
- 1-phenyl-sulfonyl-1,3-dihydro-2H-indol-2-ones have already been described as ligands of the vasopressin receptors.
- WO 93/15051, WO95 / 18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/064668, WO 01/98295, WO05 / 021534 and WO05 / 030755 describe compounds which have been disclosed by US Pat Oxindol scaffold are derived and carry an arylsulfonyl group in 1-position. These compounds differ significantly in the substitution in the 3-position.
- WO 93/15051 and WO 98/25901 describe 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-one as ligands of vasopressin receptors in which the oxindole skeleton in the 3-position is represented by two alkyl radicals substituted, which may also be linked to a cycloalkyl radical (spiro linkage).
- the spiro ring may contain heteroatoms such as oxygen and nitrogen (optionally with substituents).
- WO 95/18105 describes 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-one as ligands of the vasopressin receptors which carry a nitrogen substituent in the 3-position.
- a radical is attached, which is selected from alkyl, cycloalkyl, phenyl and benzyl (each optionally with substituents).
- WO 03/008407 describes 1-phenylsulfonyloxindoles in which pyridylpiperazines are bonded to the oxindole in the 3-position via an oxycarbonyl group.
- the object of the present invention is to provide further compounds for the treatment or prophylaxis of various vasopressin-dependent diseases.
- the compounds should have advantages over known compounds, such as improved metabolic stability and / or improved pharmacological activity.
- the benefits may be demonstrated using, for example, suitable models that allow prognosis for the desired application in the treatment of patients.
- A is an aromatic, heteroaromatic, partially aromatic or partially heteroaromatic mono- or bi-cyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms as ring members, which additionally contains 0, 1, 2, 3 or 4 identical or different hetero atoms independently selected from the group consisting of nitrogen, oxygen and sulfur, which may contain as ring members and which is substituted with the radical R a 1 and also with one, two or three radicals R A 11 , R A 12 and / or R A 13 may be substituted independently of one another and independently of their occurrence from the group consisting of bromine, chlorine, fluorine, CN, CF 3 , OCF 3 , OCHF 2 , OH, O-C 1 -C 4 -alkyl and C 1 -C 4 -alkyl;
- R A 1 is selected from the group consisting of
- Ci-C4-alkylene-R A 2 Co-C3 alkylene-0-C2-C4-alkylene-R A 2, C 0 -C 3 alkylene NR A 3 -C 2 -C 4 -alkylene R is A 2 ;
- R A 3 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
- R A 2 is selected from the group consisting of
- R A 4 is independently of its occurrence selected from the group consisting of the respective individual residues
- R A 5 is selected from the group consisting of hydrogen, hydroxy and optionally substituted C 1 -C 4 -alkyl; such as hydroxy-C 1 -C 4 -alkyl, in particular hydrogen and C 1 -C 4 -alkyl;
- B is an aromatic, heteroaromatic, partially aromatic or partially heteroaromatic mono- or bicyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms as ring members, which is additionally 0 , 1, 2, 3 or 4 identical or different heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur, may contain as ring members and which may be substituted by one, two or three radicals R B 1 , R B 2 and / or R B 3 , wherein R B 1 , R B 2 and R B 3 are independently and independently of their respective
- Occurs selected from the group consisting of chlorine, bromine, fluorine, CN, CF 3 , OCF 3 , OCHF 2 , OH, O-Ci-C 4 alkyl and Ci-C 4 alkyl;
- R 1 is selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, CN, CF 3 , OCF 3 , OCHF 2 , O-C 1 -C 4 -alkyl, C 1 -C 4 -alkyl,
- Ci-C 4 alkenyl and C 2 -C 4 alkynyl Ci-C 4 alkenyl and C 2 -C 4 alkynyl
- R 2 is selected from the group consisting of hydrogen, C 1 -C 4 -alkyl,
- R Y 1 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
- R Y 2 is selected from the group consisting of hydrogen, phenyl, C 1 -C 6 -alkyl and C 3 -C 7 -cycloalkyl,
- R ⁇ 1 and R ⁇ 2 are also taken together, together with the atom to which they are attached, to form a 4-, 5-, 6- or 7-membered, saturated or unsaturated carbocyclic ring containing a nitrogen atom containing one or two substituents R ⁇ 6 and / or R ⁇ 7 have each independently and independently of their occurrence may be selected from the group consisting of fluoro, OH, OC 1 -C 4 alkyl, phenyl and C 1 -C 4 alkyl; or in the case of adjacent position to each other R ⁇ 6 and R 7 together with the respective carbon atom to which they are attached, can form a fused substituted or unsubstituted benzene ring;
- R ⁇ 3 is selected from the group consisting of hydrogen and methyl
- R ⁇ 4 is a saturated, partially saturated or unsaturated ring having 1, 2, 3, 4, 5, or 6 C atoms as ring members, which additionally 1, 2, 3 or 4 identical or different heteroatoms, independently selected from Group consisting of nitrogen, oxygen and sulfur, which may contain as ring members and which may be substituted by one or two radicals R ⁇ 8 and / or R ⁇ 9 , wherein R ⁇ 8 and R ⁇ 9 are independently selected and independently of their occurrence are selected from the group consisting of chlorine, bromine, fluorine, CN, OH, C 1 -C 4 alkyl and C 1 -C 4 alkyl;
- the invention therefore relates to compounds of the formula (I), their tautomers, their prodrugs and in particular their physiologically tolerated salts.
- a preferred embodiment of the present invention relates to compounds of the general formula (I) as described above or in claim 1, their tautomers, their prodrugs and their physiologically tolerable salts, wherein the variables A, R A 1 , R A 2 , RA 3 , RA 4 , RA 5 , B, R 1 , R 2 , Y, R Y 1 , R Y 2 , R Y 3 and R ⁇ 4 independently of one another and preferably in combination have the following meanings:
- A is a ring selected from the group consisting of benzene, Benzo [1, 3] dioxole, thiophene and pyridine, which is substituted with the radical R A 1 and may be additionally substituted in addition with one or two radicals R A 11 and / or R A 12 , independently of one another and independently of their respective occurrence are selected from the group consisting of chlorine, fluorine, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl and propyl;
- R A 1 is selected from the group consisting of
- R A 3 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
- R A 2 is selected from the group consisting of
- R A 4 is independently of its occurrence selected from the group consisting of the respective individual residues
- R A 5 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
- R B is an aromatic or heteroaromatic mono- or bicyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms as ring members, the additionally 0, 1, 2, 3 or 4 identical or different hetero atoms independently selected from the group consisting of nitrogen, oxygen and sulfur, which may contain as a ring member and with one or two radicals R B 1 and / or R B 2 may be substituted, wherein R B 1 and R B 2 are independently selected from the group consisting of chlorine, fluorine, CN, OH, O-Ci-C 4 alkyl and dC 4 alkyl;
- R 1 is selected from the group consisting of hydrogen, chlorine, fluorine,
- R 2 is selected from the group consisting of hydrogen, chlorine, fluorine and methyl
- R ⁇ 1 is selected from the group consisting of
- R Y 2 is selected from the group consisting of hydrogen, phenyl and C 1 -C 4 -alkyl;
- R ⁇ 1 and R ⁇ 2 are also taken together, together with the respective atom to which they are bonded, to form a 5- or 6-membered saturated or unsaturated carbocyclic ring containing a nitrogen ring atom which may have a substituent R ⁇ 6 selected from is selected from the group consisting of C 1 -C 4 -alkyl, O-Ci-C 4 -alkyl, fluorine and OH;
- R Y 3 is hydrogen
- R ⁇ 4 is a 5-membered or 6-membered heteroaromatic ring having 1, 2, 3, 4 or 5 C atoms as ring members which additionally has 1, 2, 3 or 4 identical or different heteroatoms, independently selected from the group, consisting of nitrogen, oxygen and sulfur, containing as ring member and which may optionally be substituted with a radical R ⁇ 8 , wherein R ⁇ 8 is selected independently of the occurrence of the group consisting of C 1 -C 4 alkyl.
- a particularly preferred embodiment relates to compounds of general formula (I) as described above or in claim 1 or 2, wherein
- A is a benzene ring which is substituted with the radical R A 1 and may additionally be substituted by a radical R A 11 ;
- R A 1 1 is selected from the group consisting of chloro, fluoro, methoxy, ethoxy, propoxy, methyl and ethyl;
- R A 1 is a radical selected from the group consisting of the respective individual radicals / ⁇ M - H / ⁇ M / C r C 4 - ⁇ kyl ⁇ x / C 1 -C 4 -alkyl * N * N * N * N
- B is a ring selected from the group consisting of benzene, pyridine,
- Thiophene and quinoline each of which may be substituted with 1 or 2 radicals R B 1 and / or R B 2 , wherein R B 1 and R B 2 are independently selected from the group consisting of chlorine, fluorine, CN, methyl Ethyl, hydroxy, methoxy and ethoxy;
- R 1 is selected from the group consisting of hydrogen, chlorine, fluorine, CN, methoxy and methyl;
- R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
- Y is a radical selected from the group consisting of the respective individual radicals
- R Y 4 is a radical selected from the group consisting of pyridine,
- R ⁇ 6 is selected from the group consisting of the radicals
- a preferred embodiment relates to compounds of general formula (I) as described above or in any one of claims 1 to 3, wherein
- A is selected from the group consisting of the respective individual residues
- R A 1 is a radical selected from the group consisting of the respective individual radicals
- B is a ring selected from the group consisting of the respective individual radicals
- R B 1 and R B 2 are independently and independently selected from the group consisting of hydrogen, chlorine, fluorine, CN, methyl, methoxy and ethoxy;
- R 1 is selected from the group consisting of chlorine, fluorine, methoxy and CN;
- R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
- Y is selected from the group consisting of the respective individual radicals
- R Y 4 is selected from the group consisting of the respective individual radicals
- a particularly preferred embodiment relates to compounds of general formula (I) as described above or in any one of claims 1 to 4, wherein
- A is a radical selected from the group consisting of the respective individual radicals
- R A 1 is a radical selected from the group consisting of the respective individual residues
- B is a radical selected from the group consisting of the respective individual radicals
- R 1 is selected from the group consisting of chlorine, fluorine, and CN;
- R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
- Y is a radical selected from the group consisting of the respective individual radicals
- a very particularly preferred embodiment relates to compounds of general formula (I) as described above or in any of claims 1 to 5, wherein
- A is a radical selected from the group consisting of the respective individual radicals
- R A 1 is a radical selected from the group consisting of the respective individual radicals
- R 1 is selected from the group consisting of chlorine and CN;
- R 2 is selected from the group consisting of hydrogen and chlorine
- Y is a radical selected from the group consisting of the respective individual radicals
- a particularly preferred embodiment relates to compounds of the general formula (I) as described above or in any one of claims 1 to 6, wherein the radicals A, B, Y, R 1 and R 2 each independently have one of the meanings given above and wherein the radical R 2 is bonded to the 6-position of the oxindole ring skeleton, and also tautomeric forms, prodrugs and, in particular, physiologically tolerable salts of compounds of the formula (I).
- a particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and
- mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
- Another particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and
- mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
- Another particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and Y for the rest
- mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
- a further particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 may each independently of one another have the meanings given above or in claims 1 to 8, and
- mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
- a very particularly preferred embodiment of the present invention relates to compounds of the general formula (Ia), wherein the radicals R 1 , R 2 , RA 2 , RA 1 1 , RB 1 , RY 1 and R ⁇ 2 have one of the meanings given above and wherein X is O or S, preferably O,
- radicals A, B, Y, R 1 and R 2 are each independently one of the meanings given above and in which the radical Y on the C atom which carries the radical R y 4 , the S configuration and the carbon atom in the position 3 of the oxindol-2-one skeleton either the (R) - or the ( S) configuration, as well as tautomeric forms, prodrugs and in particular physiologically acceptable salts of compounds of the formula (I) or (Ia).
- At least one compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 for use as a medicament there is provided at least one compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 for use as a medicament.
- composition containing at least one compound of the general formula (I) or (La) as described above or in any one of claims 1 to 17.
- the use of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16 for the treatment and / or prophylaxis of at least one disease is selected the group consisting of hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis occurring in chemotherapy, and / or motion sickness and / or for the manufacture of a medicament for the treatment and / or prophylaxis of at least one of the said diseases , provided.
- PTCA percutaneous transluminal coronary angioplasty
- the use of at least one compound of the general formula (I) or (La) as described above according to one of claims 1 to 16 for the treatment of sleep disorders and / or for the preparation of a medicament for the treatment of sleep disorders provided.
- a method for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood coagulation disorders occur and delaying voiding in a patient in that an effective amount of at least one compound of the general formula (I) or (LA) described above or according to one of Claims 1 to 16 is administered to the patient.
- a method for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalaemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis arising in chemotherapy, and Motion sickness in a patient, characterized in that the patient is administered an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16.
- a method for the treatment and / or prophylaxis of affective disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
- a method of treating anxiety disorders and / or stress dependent Anxiety disorders in a patient characterized in that the patient is administered an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16.
- a method for treating memory impairment and / or Alzheimer's disease in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
- a method for treating psychosis and / or psychotic disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
- a method for treating Cushing's syndrome in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to one of Claims 1 to 16 are administered.
- a method for the treatment of sleep disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to one of claims 1 to 16 described.
- a method of treating depressive disorders in a patient in that the patient is provided with an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of Claims 1 to 16.
- a method of treating and / or preventing vasomotor symptoms and / or thermoregulatory dysfunctions, such as the hot flush symptom, in a patient is characterized by providing the patient with an effective amount of at least one of A compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 is administered.
- a method for the treatment and / or prophylaxis of schizophrenia and / or psychosis, in a patient is characterized in that the patient is provided with an effective amount of at least one compound of the general formula (I) or (La) , as described above or according to any one of claims 1 to 16, is provided.
- a process for the preparation of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16 is characterized in that it has been prepared by the person skilled in the art Knowledge of the technical teaching according to the invention in execution and / or in an analogous version of known method steps can be produced provided.
- a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they have a selectivity to the vasopressin receptor subtype V1b against at least one of the closely related vasopressin / oxytocin receptor subtypes (for example vasopressin V1a, vasopressin V2 and / or oxytocin).
- a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they have improved metabolic stability.
- the metabolic stability of a compound can be measured, for example, by incubating a solution of this compound with liver microsomes from certain species (for example, rat, dog or human) and determining the half-life of the compound under these conditions (RS Obach, Curr Opin Drug Discov Devel. 2001, 4, 36-44). It can be concluded from greater half-lives on improved metabolic stability of the compound. Stability in the presence of human
- Liver microsomes are of particular interest as they allow prediction of metabolic degradation of the compound in the human liver. Compounds with increased metabolic stability (measured in the liver microsome test) are therefore likely to degrade more slowly also in the liver. The slower metabolic degradation in the liver can lead to higher and / or longer-lasting concentrations (effective levels) of the compound in the body, so that the elimination half-life of the compounds according to the invention is increased. Increased and / or longer lasting levels of activity may result in better efficacy of the compound in the treatment or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
- improved metabolic stability can lead to increased bioavailability after oral administration, as the compound undergoes less metabolic degradation in the liver (so-called "first pass effect") after absorption in the intestine.An increased oral bioavailability may be due to increased concentration (level of action ) of the compound lead to a better efficacy of the compound after oral administration.
- a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they are available in patients or relevant animal models which allow prognostic statements for use in the treatment compared to those of the prior art Technically known oxindole compounds, have improved pharmacological activity.
- a further preferred embodiment relates to compounds of the general formula (I) selected from the group consisting of the examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 listed below, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 and 91, and tautomeric forms, prodrugs and in particular physiologically acceptable salts, and non-salt forms of Compounds of the formula (I). Particularly preferably, the abovementioned compounds are provided in
- a further preferred embodiment relates to compounds of the general formula (I) or (La) selected from the compounds of Examples 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 listed below , 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 , 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 , 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171,
- the compounds according to the invention can be present as a mixture of diastereomers or as a mixture of diastereomers in which one of the two diastereomers is enriched or as essentially diastereomerically pure compounds (diastereomeric excess of> 90%).
- the compounds are present as substantially diastereomerically pure compounds.
- the respective diastereomers may, in turn, be present as a mixture of enantiomers (for example as a racemate), as a mixture of enantiomers in which one of the two enantiomers is enriched, or as substantially enantiomerically pure compounds (enantiomeric excess ee> 90%).
- the respective diastereomers are present as substantially enantiomerically pure compounds.
- Particularly preferred are compounds that are substantially diastereomerically pure and enantiomerically pure (> 90%, ee> 90%).
- Physiologically acceptable salts in the sense of the description, unless stated otherwise, can be formed, for example, with the following anions:
- alkyl For the purposes of the present description, unless stated otherwise, the terms “alkyl”, “cycloalkyl”, “alkoxy”, “haloalkyl”, “alkenyl”, “alkynyl” or “alkylene” and radicals derived therefrom always include both unbranched and branched alkyl, cycloalkyl, alkoxy, haloalkyl, alkenyl, alkynyl or alkylene.
- Ci-C ⁇ -alkyl and Ci-C 4 -alkyl in the sense of the description, unless otherwise stated, mean an optionally substituted straight-chain or branched saturated hydrocarbon chain with the respective number of carbon atoms from 1 to 6 or from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methyl-butyl, 1, 2-dimethylpropyl, 1 , 1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2,3-dimethylbutyl, 1, 1-dimethylbutyl, 2.2 Dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl,
- C 1 -C 4 -alkyl is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or t-butyl.
- d-Ce-alkoxy or "-O-Ci-C 6 -alkyl” means in the sense of the description, unless otherwise stated, an oxygen-bound optionally substituted Ci-C ⁇ -alkyl group, as above is defined.
- C 3 -C 7 -cycloalkyl in the sense of the description, unless stated otherwise, means an optionally substituted saturated hydrocarbon ring having 3 to 7 ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- dC 6 -haloalkyl or dC 4 -haloalkyl is, in the context of the description, unless otherwise stated, an optionally substituted one
- C 2 -C 6 -alkenyl in the sense of the description, unless stated otherwise, means an optionally substituted branched or unbranched hydrocarbon chain containing at least one double bond having 2 to 6 carbon atoms.
- C 2 -C 6 alkenyl contains one or two double bonds, most preferably one double bond.
- Alkenyl groups are those as mentioned above for alkyl, which groups contain one or two double bonds, such as vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2 -propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl 3-butenyl, 3-methyl-3-butenyl, 1, 1-dimethyl-2-propenyl, 1, 2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4 -Hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl 3-pentenyl
- C 2 -C 6 -alkynyl the purposes of the description, unless stated otherwise, an optionally substituted branched or unbranched hydrocarbon chain containing at least one triple bond having 2 to 6 carbon atoms.
- C 2 -C 6 alkynyl contains one or two triple bonds, most preferably a triple bond.
- alkynyl groups are those as mentioned above for alkyl, which groups contain one or two triple bonds, such as ethynyl, 1-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl , 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1, 1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl , 1-methyl-2-pentynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3 Methyl 4-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl
- 3- to 10-membered carbocycle or “4 to 7-membered carbocyclic ring” or “carbocyclic ring having 2 to 10 C-atoms” mean in the sense of the description, unless stated otherwise, an optionally substituted saturated or completely or partially unsaturated hydrocarbon ring having 3 to 10 carbon atoms or 4 to 7 carbon atoms or 2-10 C atoms as ring atoms, such as cyclopropyl, cyclobutyl , Cyclopentyl, cyclohexy, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl.
- the carbocyclic ring may also contain heteroatoms as ring atoms.
- the heteroatom ring members may optionally be included in place of the C-atom ring members or in addition to the C-atom ring members.
- Halogen is, in the sense of the description, unless otherwise stated, a halogen atom selected from fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine.
- C 1 -C 6 -haloalkyl or "C 1 -C 4 -haloalkyl” in the sense of the description, unless stated otherwise, denote an optionally substituted alkyl radical as defined above which is partially or completely independent of one another by one or more identical or different radicals selected from the group consisting of fluoro, chloro, bromo and iodo, eg CH 2 F, CHF 2 , CF 3 , CH 2 Cl, 2-fluoroethyl, 2-chloroethyl, 2,2,2-trifluoroethyl.
- substituents in the sense of the description and the terms “substituted”, “optionally substituted” and “in each case unsubstituted or substituted ", unless stated otherwise, include: halogen, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NO 2 , NH 2 , OH, COOH, in each case branched or unbranched, optionally substituted C 1 -C 6 -alkyl , C 3 -C 7 -cycloalkyl, C 1 -C 6 -alkylene-O-C 1 -C 6 -alkyl or C 1 -C 6 -thioalkyl, O-C 1 -C 4 -alkyl, N (C 1 -C 4 -alkyl) 2 , NH (C 1 -C 4 -alkyl), aryl, -O-aryl, C 1 -C 4 -alkylene-O-aryl, NHCO-C
- parenthesized expressions with subscripts are understood to mean, unless otherwise stated, that the meanings of the radicals in parentheses may be the same or different.
- N (C 1 -C 4 -alkyl ky I) 2 in accordance with the description for N (Ci-C4 alkyl) (Ci-C 4 alkyl), wherein the two residues (Ci-C 4 alkyl) may be the same or different.
- the symbol () represents a single bond which, if bound to a center of chirality, is intended to mean that the corresponding compound is denoted either as an approximately 1: 1 mixture (Racemat, (R / S) form) of the two enantiomeric forms with respect to the center of chirality or as separate (R) -enantiomers and / or (S) -enantiomers with respect to the center of chirality.
- (CH 2 ) i, 2 means that the parenthetical expression occurs once or twice.
- aromatic, heteroaromatic, partially aromatic or teilheteroaromatischer mono- or bicyclic ring means in the sense of the description, unless otherwise stated, a mono-or bicylic ring of carbon atoms (“aromatic” or “partially aromatic”) or a Combination of C and heteroatoms (“heteroaromatic” or “partially heteroaromatic”) is constructed in each case as ring members and an aromatic number of double bondings in the ring ("monocyclic") or in the two rings (“bicyclic") (“aromatic or "heteroaromatic") or only in one of the rings (“partially aromatic” or “partially heteroaromatic”).
- aromatic rings examples include phenyl, naphthyl, fluorenyl, indenyl and phenanthrenyl, with phenyl and naphthyl, which may be 1-naphthyl or 2-naphthyl, being preferred. Most preferred is phenyl.
- heteroaromatic rings are 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-thiazolyl, 5 Thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 3-isothiazolyl, 4-isothiazolyl , 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 3-isoxazolyl, 4-isoxazolyl, 5-isothiazolyl, 2-imi
- partially aromatic rings are: 5,6,7,8-tetrahydro-naphthalen-1-yl, 5,6,7,8-tetrahydro-naphthalen-2-yl, and indan-4-yl, indan-5 yl.
- Examples of partially heteroaromatic rings are: benzo [1,3] dioxol-4-yl, benzo [1,3] dioxol-5-yl, 2,3-dihydro-benzo [1,4] dioxin-5-yl, and 2,3-dihydrobenzo [1, 4] dioxin-6-yl.
- saturated or completely or partially unsaturated carbocyclic ring or “saturated or unsaturated carbocyclic ring” in the meaning of the description, unless otherwise stated, mean a ring formed from C atoms and optionally one or more heteroatoms or formed ring system, the has no double bond present in the ring ("saturated") or one or more conjugated or unconjugated or partially conjugated double bonds (“partially or completely unsaturated” or “unsaturated”) .
- the carbocyclic ring may be a mono-, bi- or tricyclic ring
- a bicyclic or tricyclic saturated carbocycle may, unless stated otherwise, be a bicycloalkyl or tricycloalkyl radical having 2 to 10 carbon atoms In a tricycloalkyl
- the ring system preferably contains from 6 to 10, more preferably from 6 to 10, carbon atoms. Examples of a bicycloalkyl group include indanyl, camphyl and norborn
- the compounds according to the invention are administered by different routes (for example intravenously, intramuscularly, orally) after administration, especially orally, effectively.
- the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of diseases in which the course of the disease depends, at least in part, on vasopressin, i. Diseases that show an elevated vasopressin level, which may contribute indirectly or indirectly to the clinical picture.
- the present invention provides the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
- diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
- the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of the following diseases: hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasia), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalaemia, Schwartz-Bartter syndrome, gastrointestinal disturbances, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, vomiting on chemotherapy, and motion sickness.
- diseases hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasia), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex,
- the compounds of the present invention may also be used to treat various vasopressin-dependent disorders having central nervous causes or changes in the hypothalamic pituitary adrenal axis (HPA), for example, affective disorders such as depressive disorders and bipolar disorders. These include, for example, dythymous disorders, phobias, post-traumatic stress disorder, general anxiety disorders, panic disorders, seasonal depression and sleep disorders. Likewise, the compounds of the invention can be used for the treatment of anxiety disorders and stress-related anxiety disorders, such as generalized anxiety disorders, phobias, post-traumatic anxiety disorders, panic anxiety disorders, obsessive-compulsive
- HPA hypothalamic pituitary adrenal axis
- anxiety disorders acute stress-related anxiety disorders and social phobia.
- the compounds of the invention can also be used for the treatment of memory disorders, Alzheimer's disease, psychosis, psychotic disorders, sleep disorders and / or the Cushing syndrome and all stress-dependent diseases.
- the present invention also relates to pharmaceutical compositions containing an effective dose of a compound of the invention or a pharmaceutically acceptable salt thereof and suitable pharmaceutical carriers (excipients).
- excipients are chosen according to the pharmaceutical form and the desired mode of administration.
- the compounds of the general formula (I) according to the invention or optionally suitable salts of these compounds can be used for the preparation of pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration and animals in uniform Administration forms mixed with conventional pharmaceutical carriers for the prophylaxis or treatment of the above disorders or diseases.
- the suitable unitary dosage forms include forms for oral administration such as tablets, gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms of subcutaneous, intramuscular or intravenous administration and forms of rectal administration.
- the compounds of the invention can be used in creams, ointments or lotions.
- the dose of the active principle may vary between 0.01 and 50 mg per kg body weight and per day.
- Each unit dose may contain from 0.05 to 5000 mg, preferably from 1 to 1000 mg, of the active ingredient in combination with a pharmaceutical carrier. This unit dose can be administered 1 to 5 times a day, so that a daily dose of 0.5 to 25000 mg, preferably 1 to 5000 mg, is administered.
- a solid composition is prepared in the form of tablets, the main ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
- a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
- the tablets may be coated with sucrose, a cellulose derivative or other suitable substance or otherwise treated to have sustained or delayed activity and to continuously release a predetermined amount of the active principle.
- a preparation in the form of gelatin capsules is obtained by mixing the active ingredient with an extender and incorporating the resulting mixture into soft or hard gelatin capsules.
- a preparation in the form of a syrup or elixir or for administration in the form of drops may contain active ingredients together with a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
- a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
- the water-dispersible powders or granules may contain the active ingredients mixed with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidones, as well as sweeteners or flavoring agents.
- Rectal administration is achieved by using suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
- Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or sterile and injectable solutions containing pharmacologically acceptable dispersants and / or wetting agents, for example, propylene glycol or polyethylene glycol.
- the active principle may also be formulated as microcapsules or centrosomes, if appropriate with one or more carriers or additives.
- compositions according to the invention may contain other active principles which may be useful for the treatment of the above-mentioned disorders or diseases.
- the present invention thus further relates to pharmaceutical compositions in which several active principles are present together, at least one of which is a compound of the invention.
- the preparation of the oxindoles according to the invention can, for example, on the in the synthetic schemes 1.A and 1.B outlined path.
- the variables have the same meanings as in the general formula (I) or (La).
- the 3-hydroxyoxindoles (VI) can be prepared by adding lithium-organic or Grignard compounds to the 3-keto group of the substituted isatin V in an ethereal solvent such as THF.
- THF ethereal solvent
- the lithium species can be obtained from the iodo-aryl compound IV by treatment with organolithium reagents, such as n-butyllithium, in THF at low temperatures.
- the corresponding Grignard compound can be prepared by treatment with magnesium in an ethereal solvent such as THF.
- the cyclic acetal (IV) can be prepared in two stages (methylation of phenol-oxygen followed by protection of the aldehyde as acetal) from commercially available 3-hydroxy-4-iodobenzaldehyde (II).
- the isomeric building block protected aldehyde function para to the methoxy group
- the building blocks with protected aldehyde function which is used for the synthesis of compounds of the invention may be in the 2-position of the phenyl ring A fluorine, ethoxy or methyl as the radical R A 11 carry.
- metallated heteroaromatics bearing a protected formyl group may be reacted in an analogous manner (protecting the formyl function as a cyclic acetal followed by lithium-halogen exchange or insertion of magnesium into the heteroaryl-halo - Bond) are produced, eg from commercially available 2-bromo-4-formyl-3-methoxypyridine, 6-bromo-2-formylpyridine, 5-bromo-3-formylpyridine, 2-bromo-4-formylpyridine, 2-bromo-5-formylpyridine, 4-bromo 2-formylthiophene, 3-bromo-2-formylthiophene, 5-bromo-2-formylthiophene or 3-bromo-4-formylthiophene.
- radical A in the general formula (I) is a 2-methoxy-pyridin-3-yl radical
- the aldehyde can be brominated ortho to the methoxy group (European Journal of Medicinal Chemistry (1977), 12 (6), 531-6) and the 5-bromo-6-methoxypyridine-3-carbaldehyde thus obtained subsequently as cyclic acetal to be protected.
- the lithium-organic species obtained by lithium-halogen exchange with butyllithium can be added to substituted islets in the manner described above.
- the 3-hydroxy-oxindoles (VI) can be converted into the compounds (VII) which have a
- Leaching group LG wear in the 3-position are transferred, wherein the leaving group LG usual leaving groups, such as halides, mesylate or tosylate, may be.
- LG chlorine
- the intermediate (VII) by treatment of the alcohol VI with thionyl chloride in the presence of a Base, such as pyridine, in a solvent, such as dichloromethane.
- the compounds (VII) are then reacted in the presence of a base such as ⁇ /, ⁇ / diisopropylethylamine with primary or secondary amines YH in a solvent such as dichloromethane to give the corresponding 3-aminooxindoles (VIII) in which the linkage of the radical Y with the 3-carbon atom of the oxindole skeleton takes place via a nitrogen atom.
- a base such as ⁇ /, ⁇ / diisopropylethylamine
- a solvent such as dichloromethane
- One of the preferred radicals Y is (S) -2-oxazol-2-yl-pyrrolidin-1-yl.
- the corresponding 2- (S) -pyrrolidin-2-yl-oxazole can be prepared in the form of the HBr salt according to US 2003/0069223.
- Y are (S) -2-oxazol-2-yl-piperidin-1-yl, (2S, 4R) -4-hydroxy-2-oxazol-2-yl-pyrrolidin-1-yl and (S) 1-oxazol-2-yl-ethylamino.
- the HBr salt of (2S, 4R) -4-acetoxy-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available Cbz / tert-butyl-protected (2S, 4R ) -4-hydroxyproline (Cbz-Hyp (Tbu) -OH, Bachern).
- the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
- the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid. Under these conditions, the terf-butyl protecting group is also cleaved and the resulting alcohol is acetylated. Under the conditions of the aldehyde release (synthesis scheme 1.B, reaction of (IX) to (X)), the deacetylation also takes place. This leads to the (2S, 4R) -4-hydroxy-2-oxazol-2-yl-pyrrolidin-1-yl compounds of the invention.
- (S) -1-oxazol-2-yl-ethylamine can be prepared from phthalimide-protected L-alanine in three steps.
- Phthalimide-protected L-alanine (Pht-Ala-OH) can be prepared, for example, by treatment with oxalyl chloride and catalytic amounts of N, N-dimethylformamide (DMF) in a suitable solvent (eg dichloromethane) are converted into the corresponding acid chloride (Pht-Ala-Cl).
- DMF N, N-dimethylformamide
- the phthalimide-protected oxazole building block can be obtained by treatment of the acid chloride with 2-trimethylsilanyl-2H- [1,2,3] triazole and heating in sulfolane. Removal of the phthalimide protecting group, for example with hydrazine hydrate in ethanol, yields the free (S) -1-oxazol-2-yl-ethylamine.
- the resulting free hydroxy function is alkylated in a second step with an alkyl halide (eg, methyl iodide) after prior deprotonation with a strong base (eg, NaH).
- an alkyl halide eg, methyl iodide
- a strong base eg, NaH
- the Cbz protecting group of the amino function is removed with a hydrobromic acid / glacial acetic acid mixture.
- (2S, 4R) -4-TeAt-butoxy-2-oxazol-2-yl-pyrrolidine can be prepared by catalytic hydrogenation (removal of the Cbz protecting group) from (2S, 4R) -4-terf-butoxy-2-oxazole-2 -yl-pyrrolidine-1-carboxylic acid benzyl ester.
- the HBr salt of (S) -2-methyl-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available (S) -2-methylpyrrolidine-2-carboxylic acid (H-alpha Me-Pro-OH, Bachern).
- the amino function is N-protected with a protecting group (e.g., Cbz) and then coupled with aminoacetaldehyde dimethyl acetal using a coupling reagent (e.g., EDCI / HOBt) in a suitable solvent (e.g., DMF).
- a coupling reagent e.g., EDCI / HOBt
- a suitable solvent e.g., DMF
- the aldehyde function is released by treatment with an acid (eg, aqueous hydrochloric acid) in an organic solvent (eg, acetone).
- the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
- the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
- the HBr salt of (2S, 4R) -4-fluoro-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available (2S, 4R) -4-fluoropyrrolidine-2-carboxylic acid.
- the TFA salt of (S) -3-pyrrolidin-2-yl- [1,2,4] oxadiazole can be prepared in three stages as shown in Synthetic Scheme 6 and analogously to WO2002 / 102799.
- hydroxylamine is added to commercially available (S) -1-N-Boc-2-cyano-pyrrolidine.
- the product obtained and trimethyl orthoformate are condensed together with acid catalysis (para-toluenesulfonic acid). Removal of the Boc protecting group with trifluoroacetic acid eventually results in the desired product.
- the TFA salt of (S) -2-pyrrolidin-2-yl- [1, 3,4] oxadiazole can also be prepared as shown in Synthetic Scheme 6 and analogously to WO2002 / 102799 in three steps.
- a first step commercially available Boc-Pro-OMe is reacted with hydrazine to give the corresponding hydrazide.
- a second step the resulting hydrazide is condensed with trimethyl orthoformate under acid catalysis (p-TsOH). Removal of the Boc protecting group with trifluoroacetic acid results in the desired product.
- the HBr salt of 4-methyl-2- (S) -pyrrolidin-2-yl-oxazole can be prepared from commercially available Cbz-Pro-OH, as shown in Synthetic Scheme 7.
- the protected amino acid is treated with 2-amino-propan-1-ol using a coupling reagent such as N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride (EDCI) in the presence of 1-hydroxy- benzotriazole, coupled in a solvent such as DMF.
- EDCI N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride
- the aldehyde function can be generated by oxidation with the Dess-Martin reagent or according to Swern (J. Org. Chem. 43, 2480 (1978)).
- the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
- the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
- the HBr salt of 5-methyl-2- (S) -pyrrolidin-2-yl-oxazole can be prepared starting from commercially available Cbz-Pro-OH (Synthetic Scheme 8).
- the protected amino acid is coupled with 1-amino-propan-2-ol using a coupling reagent (e.g., EDCI / HOBt) in a suitable solvent (e.g., DMF).
- a coupling reagent e.g., EDCI / HOBt
- a suitable solvent e.g., DMF
- the aldehyde function can be generated by oxidation with the Dess-Martin reagent or according to Swern (J. Org. Chem. 43, 2480 (1978)).
- the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane. Finally, the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
- the compounds (VIII), (IX), (X) and (XI) can be obtained as a mixture of diastereomers.
- a separation of the two diastereomers for example, in the case of (VIII) and (X) by chromatography on silica gel using a suitable eluent, for example ethyl acetate in dichloromethane or methanol in dichloromethane.
- a suitable eluent for example ethyl acetate in dichloromethane or methanol in dichloromethane.
- the compounds (VIII), (IX) and (X) were processed as diastereomerically pure compounds.
- the diastereomers can in many cases be purified by chromatographic methods, for example over silica gel using a suitable eluent, such as methanol in dichloromethane, or by preparative HPLC using a suitable solvent Eluent, such as acetonitrile in water with small amounts of trifluoroacetic acid, are separated.
- a suitable eluent such as methanol in dichloromethane
- a suitable solvent Eluent such as acetonitrile in water with small amounts of trifluoroacetic acid
- the 3-hydroxy-oxindoles (XII) can be prepared by addition of lithium-organic or Grignard compounds to the 3-keto group of the substituted isatin (V).
- R A 1 1 OCH 3
- PG suitable protecting group PG, such as triisopropylsilyl
- organolithium reagents such as n-butyllithium
- the phenolic oxygen function can be alkylated with alkyl halides containing substituted amino groups R A 2 , eg by heating the phenol (XVI) with the alkylating agents R A 2 - (C 2 -C 3 alkyl) -CI in DMF in the presence of a base such as potassium carbonate in the microwave.
- a base such as potassium carbonate in the microwave.
- the resulting Grignard solution was added to an ice-cooled solution of the 5-chloroisatin sodium salt [prepared by treating a solution of 5-chloroisatin (13.1 g, 72 mmol) in THF (400 mL) with a
- the following compounds 3 to 43 were prepared in diastereomerically pure form.
- the compounds were purified by preparative reversed-phase HPLC (mobile phase: gradient of 10% to 80% acetonitrile in water, 0.1% trifluoroacetic acid or 0.2% acetic acid as modulator) and, if they contain a basic nitrogen in the molecule, as Trifluoroacetic acid salts or acetic acid salts.
- Example 12 3- (5-Azetidin-1-ylmethyl-2-methoxy-phenyl) -5-chloro-1- (4-methoxy-benzenesulfonyl) -3 - ((S) -2-oxazol-2-yl-pyrrolidine-1 -yl) -1,3-dihydroindol-2-one,
- the compounds of the invention are antagonists of the so-called receptors of the vasopressin / oxytocin family. Such compounds can be tested in suitable assays that detect affinity for a receptor, the affinity constant Ki being a measure of the potency of the compounds and a smaller value represents a greater potency.
- the compounds of the invention were tested for their affinity for the V1b receptor in the following receptor binding assay.
- test substances were dissolved in a concentration of 10 -2 M in DMSO and further diluted in DMSO to 5x10 "4 M to 5x10" 9 M.
- This DMSO DMSO
- CHO-K1 cells stably expressed with human vasopressin V1 b receptor were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron Homogenizer at medium position 2x10 seconds and then 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
- protease inhibitors Roche complete Mini # 1836170
- the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
- Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
- membranes 50 ⁇ g / ml protein in
- Binding was determined with 1 ⁇ M AVP (Bachern # H1780). All determinations were made in triplicate. After incubation (60 minutes at room temperature), the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials. The
- Liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
- the binding parameters were calculated by nonlinear regression in SAS.
- the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem. 239 (1980)).
- the Kd value of 3 H-AVP to the recombinant hV2 receptors is 0.4 nM and was used to determine the Ki value.
- the affinities for the human vasopressin receptor V1b were measured in accordance with the above test and the affinity constants (Ki) were determined.
- Table 1 below shows the V1 b receptor affinity of selected compounds (+++ means ⁇ 10 nM, ++ means 10-100 nM and + means 100-1000 nM).
- the indicated affinities for the V1 b receptor refer to the diastereomer, which has a stronger affinity (lower Ki value) for the V1 b receptor.
- affinities for other vasopressin receptors or their subtypes e.g. V1a and V2, and the oxytocin (OT) receptor.
- the available quotients of the corresponding Ki values ie
- Ki (V1a) / Ki (V1b) can be used as a measure of a possible selectivity the compounds of the invention with respect to a particular vasopressin or oxytocin receptor serve.
- Vasopressin V1a receptor binding test
- test substances were dissolved in a concentration of 10 -2 M in DMSO.
- concentration of 10 -2 M in DMSO was carried out in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4).
- CHO-K1 cells stably expressed with human vasopressin V1a receptor 100
- Binding test The binding test was carried out in accordance with the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
- Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
- membranes (20 ⁇ g / ml protein in incubation buffer) of CHO-K1 cells with stably expressed human V1a receptors (cell line hV1 a_5_CHO) were incubated with 0.04 nM 125 I-AVP (8 ⁇ g / ml).
- Vasopressin NEX 1278 in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or additionally incubated with increasing concentrations of test substance (displacement experiment). Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). Triple determinations were made.
- the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
- the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
- Receptors were determined in saturation experiments. A Kd value of 1.33 nM was used to determine the Ki value.
- test substances were dissolved in a concentration of 10 -2 M in DMSO. Further dilution of this DMSO solution was carried out in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4).
- CHO-K1 cells stably expressed with human vasopressin V2 receptor (clone 23) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron homogenizer at medium position 2x10 seconds and then for 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
- the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
- Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
- membranes 50 ⁇ g / ml protein in incubation buffer
- CHO-K1 cells with stably expressed human V2 receptors (cell line hV2_23_CHO) with 1-2 nM 3 H-AVP (8-Arg vasopressin, Perkin Elmer # 18479) in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or in addition with increasing
- test substance concentration experiment
- Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). Triple determinations were made. 102
- the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
- the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
- the binding parameters were calculated by nonlinear regression in SAS.
- the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem., 107, 220-239 (1980)).
- the Kd value of 3 H-AVP to the recombinant hV2 receptors is 2.4 nM and was used to determine the Ki value.
- the substances were dissolved in a concentration of 10 "2 MM in DMSO and diluted with incubation buffer (50 mM Tris, 10 mM MgCl 2, 0.1% BSA, pH 7.4).
- Confluent HEK-293 cells with transiently expressed recombinant human oxytocin receptors were centrifuged at 750 xg for 5 minutes at room temperature. The residue was taken up in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH 7.4 and Roche Complete protease inhibitor) and subjected to 20 minutes at 4 0 C to osmotic shock. Thereafter, the lysed cells were centrifuged at 750 for 20 minutes at 4 0 C, the residue taken up in incubation buffer, and aliquots of 10 7 cells / ml. The aliquots were up to the 103
- the binding parameters were calculated by nonlinear regression analysis (SAS), analogous to the program LIGAND by Munson and Rodbard (Analytical Biochem 1980, 107: 220-239).
- SAS nonlinear regression analysis
- the Kd value of 3 H-oxytocin to the recombinant hOT receptors is 7.6 nM and was used to determine the Ki value.
- the metabolic stability of the compounds of the invention was determined in the following test.
- test substances are incubated in a concentration of 0.5 ⁇ M as follows:
- Potassium phosphate buffer pH 7.4 preincubated at 37 ° C for 5 min.
- the start of the reaction is carried out by the addition of NADPH (1 mg / ml). After 0, 5, 10, 15, 20 and 30 min, aliquots are removed and the reaction is stopped with the same volume of acetonitrile and cooled down. The samples are frozen until analysis.
- the half life of the compound can be calculated assuming a first order kinetics from the decrease in the concentration of the compound over time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74206505P | 2005-12-02 | 2005-12-02 | |
DE102005059484 | 2005-12-02 | ||
PCT/EP2006/069180 WO2007063123A1 (de) | 2005-12-02 | 2006-12-01 | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1957480A1 true EP1957480A1 (de) | 2008-08-20 |
Family
ID=40198306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06819882A Withdrawn EP1957480A1 (de) | 2005-12-02 | 2006-12-01 | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
Country Status (5)
Country | Link |
---|---|
US (3) | US8044079B2 (de) |
EP (1) | EP1957480A1 (de) |
JP (1) | JP2009517444A (de) |
CN (1) | CN101336239A (de) |
WO (1) | WO2007063123A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5465677B2 (ja) * | 2007-12-27 | 2014-04-09 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体およびこれらのバソプレシン依存性疾病の治療用の使用 |
MX2022013749A (es) * | 2020-05-05 | 2022-11-16 | Scripps Research Inst | Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2). |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2804115B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2805536B1 (fr) | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2807038B1 (fr) * | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
US6673790B1 (en) | 2000-04-03 | 2004-01-06 | Sanofi-Synthelabo | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
FR2810320B1 (fr) | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
US7528124B2 (en) | 2003-08-28 | 2009-05-05 | Taisho Pharmaceutical Co., Ltd. | 1,3-dihydro-2H-indol-2-one derivative |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
CA2602194A1 (en) * | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |
-
2006
- 2006-12-01 WO PCT/EP2006/069180 patent/WO2007063123A1/de active Application Filing
- 2006-12-01 CN CNA2006800521835A patent/CN101336239A/zh active Pending
- 2006-12-01 US US12/095,594 patent/US8044079B2/en not_active Expired - Fee Related
- 2006-12-01 EP EP06819882A patent/EP1957480A1/de not_active Withdrawn
- 2006-12-01 JP JP2008542774A patent/JP2009517444A/ja active Pending
-
2011
- 2011-09-23 US US13/243,166 patent/US9006276B2/en not_active Expired - Fee Related
-
2015
- 2015-04-13 US US14/685,313 patent/US20150218146A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2007063123A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2009517444A (ja) | 2009-04-30 |
WO2007063123A1 (de) | 2007-06-07 |
US20130029966A1 (en) | 2013-01-31 |
US20150218146A1 (en) | 2015-08-06 |
US20100273766A1 (en) | 2010-10-28 |
US9006276B2 (en) | 2015-04-14 |
CN101336239A (zh) | 2008-12-31 |
US8044079B2 (en) | 2011-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7803834B2 (en) | Substituted oxindole derivatives, drugs containing said derivatives and the use thereof | |
DE69830403T2 (de) | Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität | |
DE69736642T2 (de) | Heterocyclische Verbindungen, ihre Herstellung und Verwendung | |
EP1487821B1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
TWI403508B (zh) | 經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途 | |
WO2006038738A1 (ja) | 受容体機能調節剤 | |
EP1866304A2 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
DE10237722A1 (de) | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase | |
JP2011516599A (ja) | ニコチン性アセチルコリン受容体サブタイプα7のモジュレーターとしてのインドール類 | |
US8431567B2 (en) | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | |
EP1861390A1 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
JP2011510030A (ja) | 置換アミノ−ベンゾイミダゾール類、該化合物を含む医薬、これらの使用及びこれらの製造方法 | |
US20120115842A1 (en) | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | |
WO2007063123A1 (de) | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung | |
WO2012022120A1 (zh) | 二氢吡唑类化合物 | |
EP3947360B1 (de) | Serotonin 5-ht2b-hemmende verbindungen | |
DE102005015957A1 (de) | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung | |
DE19945787A1 (de) | Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
DE102005014628A1 (de) | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080601 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LUBISCH, WILFRIED Inventor name: UNGER, LILIANE Inventor name: OOST, THORSTEN Inventor name: NETZ, ASTRID Inventor name: HORNBERGER, WILFRIED Inventor name: WERNET, WOLFGANG Inventor name: GENESTE, HERVE |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1118825 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20090320 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111113 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1118825 Country of ref document: HK |